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“Cancer is an expansionist disease; it invades through tissues, sets up colonies in 
hostile landscapes, seeking “sanctuary” in one organ and then immigrating to 
another. It lives desperately, inventively, fiercely, territorially, cannily and 
defensively- at times, as if teaching us how to survive. To confront cancer is to 
encounter a parallel species, one perhaps more adapted to survival than we are.” 
 
 
Siddhartha Mukherjee 
The Emperor of all Maladies 
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1. Aim and Scope 
 
Of all the cases, majority of cancer patients respond to therapeutic interventions transiently or 
incompletely. These multidrug resistant (MDR) cancer cases are either resistant to 
chemotherapy or acquire resistance during treatment. Overcoming MDR in cancer is a major 
challenge to clinicians and researchers alike. Transporter proteins of the ATP-binding cassette 
(ABC) superfamily are over-expressed on membranes of MDR cancer cells and are responsible 
for effluxing anti-cancer drugs. Amongst the ABC transporters identified from prokaryotes to 
humans- P-glycoprotein (P-gp), multidrug resistance-associated protein-1 (MRP1) and breast 
cancer resistance protein (BCRP) are the most characterized phenotypes that confer drug 
resistance.  
An interesting phenomenon has been the emergence of routinely used pharmaceutical 
excipients (surface active agents) such as surfactants, poloxamers, PEG derivatives and their 
analogues as MDR modulators. The first chapter highlights inclusion of these approved 
‘Generally Recognized As Safe’ pharmaceutical excipients in different class of nanocarriers.  
Nanoparticles offer promise as drug delivery systems mainly due to the fact that  they prevent 
recognition of drugs by efflux pumps present on cell membrane and improve drug 
accumulation at the tumor site; thereby, reducing systemic side effects or pharmacokinetic 
profiles of therapeutic molecules leading to killing of drug resistant  tumor cells. The current 
arsenal of nano-sized formulations comprise of liposomes, solid-lipid nanoparticles or polymeric 
micelles etc., which have been developed to carry anti-cancer drugs and/ or inhibitor or a 
combination thereof with the sole  aim of reversing MDR in cancer.  
In first part of this work, we formulated nanoparticles using different excipients. The aim was to 
develop nanoparticles with inherent ‘surface active’ properties (devoid of MDR inhibitor), 
which following their interaction with cell membrane would modulate P-gp function so as to 
facilitate substrate entry. The effect of excipient-based nanoparticles was evaluated on highly 
drug resistant P-gp over-expressing brain tumor cell lines.  
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Different generations of ABC inhibitors have proved disappointing due to ineffective inhibition 
of efflux transporters, inherent toxicity and low availability at tumor site. It is increasingly 
important to prevent pharmacokinetic and pharmacodynamic interactions between anti-cancer 
drug and MDR inhibitors and the resultant systemic toxicity of latter. Encapsulating MDR 
inhibitor in nanoparticles not only improves their intra-tumoral accumulation profile, it also 
prolongs inhibitor release which can lead to sustained and efficient sensitization of drug 
resistant cells towards anti-cancer drug. In the second set of this work, inhibitor-loaded 
nanoparticles were investigated. 
In this part, we further wanted to evaluate the effect of surface charge on the properties of 
MDR inhibitor-loaded nanoparticles in drug resistant and drug sensitive cell lines. Hence, first 
and third-generation P-gp inhibitors- verapamil hydrochloride and elacridar were encapsulated 
in non-ionic, cationic and anionic nanoparticles and assessed for their ability to reverse cancer 
drug resistance. Mechanism of endocytosis of nanoparticles in both cell lines were also 
investigated by using different pharmacological inhibitors. 
Two recently synthesized quinazoline compounds- KCJ-160 and KCJ-199, both exhibiting 
inhibition of BCRP and to a lesser extent of P-gp have been identified. In the last part of my 
work, both broad spectrum MDR inhibitors were formulated in nanocarriers and assessed in 
comparison to their soluble counterparts for their potency to overcome P-gp and BCRP 
mediated drug resistance in relevant cell line models.  
  2. Theoretical Background 
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2. Theoretical Background 
 
2.1. Multidrug resistance 
A principal challenge in the fight against cancer is multidrug resistance (MDR). Analogous to the 
microbial drug resistance, the ability of cancer cells to resist treatment towards a vast spectrum 
of structurally unrelated drugs is referred to as multidrug resistance in cancer. The reason why 
same chemotherapeutic treatment yields different responses in patients can be attributed to 
the degree of resistance developed by the host’s tumor cells. MDR phenotype could develop 
either due to exposure to chemotherapy for prolonged time (extrinsic) or genetic alterations in 
tumor cells (intrinsic) hampering chemotherapeutic success1. The energy driven pumping out of 
cytotoxic drugs by resistant cells leads to diminished intracellular drug concentration. It is worth 
noting that such resistance renders chemotherapy ineffective even when adequate dose of the 
drugs are administered. 
Transporters are cell membrane proteins which facilitate/ regulate permeation of low 
molecular weight compounds and ions, driven by ATP hydrolysis. Around 48 structurally related 
transporters, collectively known as the ATP-binding cassette or ABC superfamily are responsible 
for the activity of efflux pumps and subsequent resistance against the cytotoxic drug2. In fact, 
over 50% of all cancers express detectable levels of ABC transporters1. These efflux proteins are 
expressed on cell membrane and play key physiological role in modulating absorption, 
excretion, metabolism and detoxification of various substrates at pharmacological barriers such 
as blood-brain barrier (BBB), lung, liver, kidney and gut3. ABC transporters have been 
categorized into seven subfamilies (designated as ABCA-ABCG). Three families concerned with 
drug transport and their associated efflux protein are 1) B-subfamily- P-glycoprotein (P-gp/ 
ABCB1/ MDR1), 2) C-subfamily- multidrug resistance-associated protein (MRP1/ ABCC1) and 3) 
G-subfamily- breast cancer resistance protein (BCRP/ ABCG2/ MXR). P-glycoprotein, a 170kDa 
plasma membrane glycoprotein, termed P-gp for its purported function in mediating a change 
in membrane permeability, is the most extensively characterized MDR transporter of the ABC 
family4. Due to its broad substrate specificity and ubiquitous expression in most excretory and 
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barrier functional tissue, P-gp poses serious obstacle in the treatment of infectious disease, 
brain disorders and cancer5. 
2.2. MDR Inhibitors 
Soon after MDR was discovered, intensive screening of drugs already approved for other 
medical purposes that could have putative MDR modulating effects began. Many first, second, 
and third generation potent MDR modulators/ inhibitors have undergone laboratory testing 
since then6 (Fig. 1). This has been followed by clinical trials in various combinations with anti-
cancer drug to enhance the cytotoxicity against tumor cells. 
 
Figure 1: Timeline of development of MDR inhibitors 
Cyclosporine A, for example an immunosuppressant and verapamil, a calcium channel blocker 
was evaluated as the ‘first generation’ MDR inhibitors. These inhibitors exhibited high toxicity 
profiles at the concentration they were required to attenuate P-gp function which proved to be 
a limiting factor in their clinical development. First generation inhibitors showed lack of 
efficacy, severe toxicity and side effects. In many clinical trials that followed, neurological and 
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hematological toxicity were common6. Another drawback of these inhibitors was the 
chemotherapy-related toxicity. 
This led to the development of ‘second generation’ of P-gp inhibitors which were majorly 
structural analogues of first generation inhibitors. Cyclosporine analog named valspodar (PSC 
833) and R-enantiomer of verapamil amongst other second generation inhibitors exhibited 
superior MDR reversal efficacy and lower toxicity. However, the unpredictable pharmacokinetic 
interactions limited drug clearance and metabolism of chemotherapy leading to toxic plasma 
concentrations7. Their interactions with cytochrome P450 enzymes (which in turn metabolize 
certain anti-cancer drugs such as paclitaxel) lead to alteration of pharmacokinetic properties of 
such drugs. As an example, in a phase I trial, variation in paclitaxel pharmacokinetics was 
observed, when paclitaxel was administered prior to P-gp inhibitor- valspodar (PSC 833)8. 
Several inhibitors that gave promising results in vitro, ultimately failed in clinical trials. 
‘Third generation’ P-gp inhibitors were designed favoring low pharmacokinetic interactions, 
selectivity for a specific ABC transporter and low vulnerability for metabolic transformation by 
cytochrome P450 3A7. These inhibitors such as elacridar (GF- 120918), tariquidar (XR 9576), 
OC144-093 (ONT-093) etc., demonstrated MDR reversal at nanomolar range. Although, many 
compounds are under clinical trials, most studies have been discontinued before completion 
due to non-achievement of improved response rate9 or a positive benefit-risk ratio10. 
Zosuquidar (LY335979), a third-generation inhibitor when co-administered with either 
doxorubicin or etoposide in mice bearing P388/ADR murine leukemia cells resulted in increased 
life span and no apparent alteration of pharmacokinetics11. The inhibitor was also shown to 
enhance anti-tumor efficacy of paclitaxel in human non-small cell lung carcinoma xenografts 
over-expressing MDR transporters. Phase I trial of zosuquidar together with daunorubicin and 
cytarabine resulted in a ∼75 % response rate of 16 patients with acute myeloid leukemia (AML) 
demonstrating that the inhibitor can be given safely in combination with induction doses of 
conventional cytotoxic drugs12. Subsequently, in a phase I/II study in patients with non- 
Hodgkin’s lymphoma, minimal effects of zosuquidar were observed on the pharmacokinetics of 
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doxorubicin and vincristine13. However recent randomized phase III clinical trials in AML 
patients showed no overall survival although there was not much increase in toxicity 14. 
Owing to failure of MDR inhibitors in clinical trials, alternative ways and techniques of 
overcoming MDR are being explored15,16. One way is to alternate and optimize chemotherapy 
regimen or to develop novel non-P-gp substrate anti-cancer drug. As an adjunct to 
chemotherapy; inhibition of MDR using peptides, monoclonal antibodies or MDR gene 
inactivation using small interfering RNA related studies are underway to overcome MDR at 
molecular level. ‘Fourth generation’ inhibitors are being sought after and compounds with 
higher potency, safe ADMET profiles and high specificity are desirable. Certain surfactants, 
polymers and natural compounds which are inherently ‘inert’ and approved for pharmaceutical 
applications hold the potential to form fourth generation of MDR inhibitors/ modulators. 
Though the ideal compound is difficult to find in a practical sense, alternative approaches 
should also be explored. Here, we briefly discuss the surfactants and polymers which have 
consistently exhibited MDR overcoming properties. Some of the promising results are offered 
from the area of nanotechnology. Nanocarriers functionalized with ‘inert’ fourth generation 
excipients have shown enhanced ability to evade expulsion by ABC pumps, which is the prime 
focus of this review and would be covered in subsequent sections. 
2.3. Pharmaceutical excipients with P-gp inhibitory activity 
Recent literature shows P-gp modulating ability of several excipients routinely used in 
pharmaceutical formulations.  They are generally added to increase solubility of therapeutic 
drugs and are known to display safe pharmacokinetic profiles. Different classes of these 
excipients such as surfactants, lipids and pluronics are reported to chemosensitize MDR-related 
transmembrane proteins.  
Surfactants have found use as emulsifiers in NP preparation owing to their interfacial activities. 
They have a hydrophilic polar head and water soluble, lipophilic hydrocarbon tail. One of the 
initial findings on reversal of daunorubicin resistance by screening surfactants was undertaken 
by Woodcock  et al in the early 1990’s17. They observed that all the active MDR reversing 
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detergents contained (Polyethylene glycol) PEG moieties in their hydrophilic portion but bore 
no similarities in their hydrophobic segments such as Cremophor® EL (PEG 35), Solutol® HS 15 
(PEG 660 12 hydroxystearate), Tween® 80 (PEG 20)(Table 1). Rege et al18, reported, P-gp 
modulating properties of above mentioned non-ionic surfactants-Cremophor® EL, Solutol® HS 
15, Tween® 80. At a concentration range of 0 to 1 mM of these surfactants, an increase in 
apical-to-basolateral permeability (AP-BL) and decrease in basolateral-to-apical permeability 
(BL-AP) of P-gp substrate rhodamine-123 was reported. Vitamin E TPGS however showed 
reduced BL-AP permeability of substrate, only at a concentration of 0.025 mM. The mechanism 
of action of Cremophor® EL and Tween® 80 was believed to be lipid bilayer fluidization. Being 
hydrophobic, the non-ionic surfactants tend to be less toxic on cell membranes and can be 
considered safe. On the other hand, P-gp inhibitory activity of vitamin E TPGS was attributed to 
rigidization of the lipid bilayer. 
In another study, surfactant action above and below critical micellar concentration (CMC) was 
evaluated. With respect to P-gp inhibition, it was demonstrated that higher inhibition would be 
obtained if the surfactants are more active above CMC18. As in this case, they would not just 
enhance drug absorption by improving drug solubility, but as well inhibit efflux by sensitizing P-
gp embedded within cellular membranes. A surfactant based in vitro study showed that 
compounds which were neither too hydrophilic nor too hydrophobic, but had an optimal 
hydrophilic-lipophilic balance (HLB) in the range of 10-17 resulted in uptake of the anti-cancer 
drug epirubicin19. Pre-treatment with Tween® 20, Tween® 80, Myrj® 52 and Brij® 30 
significantly raised the intracellular accumulation of epirubicin in human colon adenocarcinoma 
(Caco-2) cell line and excised rat intestinal mucosa.  
With the characterization of these excipients for their P-gp modulatory activities, there has 
been a considerable focus in this area of research with many new surfactants qualifying as 
potential P-gp modulators in the last decade. Gelucire® 44/14 and Peceol® demonstrated 
downregulation in P-gp expression in Caco-2 cells by decreasing rhodamine 123 drug efflux by 
P-gp protein thereby altering intestinal absorption20. Surfactants that could modify 
pharmacokinetics of orally administered drugs, which are also P-gp substrates were 
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investigated21. For digoxin transport in the everted gut sac technique, the most effective 
excipients were in the order: Labrasol > Imwitor 742 > Acconon E = Softigen 767 > Cremphor® 
EL>migloyl > Soluto®l HS 15 > sucrose monolaureate > Tween® 20 > TPGS > Tween® 80. They 
also evaluated absorption of another drug celiprolol and concluded that mechanism of 
transport inhibition for each drug differs.  
2.4. Natural and synthetic polymers with P-gp inhibitory activity 
Polymers such as polysaccharides, PEG derivatives, dendrimers, thiolated polymers and 
amphiphilic block copolymers were researched and reported for their P-gp modulatory 
activities22,23. Amongst natural polymers, anionic polysaccharides such as xanthan and gellan 
gum, dextran, fucoidan and sodium alginate have been patented and qualified as oral 
bioavailability enhancers and their MDR overcoming abilities24. The synthetic polymers are 
routinely used in the nanocarrier drug delivery formulations lending: 1) improved drug 
solubility; 2) steady state therapeutic level; 3) reduced systemic effects of incorporated drugs in 
vivo. Hence, P-gp inhibiting properties of such polymers make their use in anti-MDR, anti-
cancer formulations desirable.  
PEG derivatives and analogues offer wide array of applications25 and constitute large number of 
potential MDR modulators23. Experiments were carried out to assess the P-gp inhibitory activity 
of PEG with different molecular weights26. It was reported that secretory transport of 
rhodamine 123 across isolated rat intestine was inhibited on adding different concentrations 
(0.1-20% w/v) of PEG and that it was not dependent on their molecular weights. Treatment 
with PEG led to an enhanced accumulation of paclitaxel and doxorubicin in Caco-2 cells27 and 
higher rates of intestinal transport and absorption of prednisolone and quinidine in rats28. 
When compared to the activity of Cremophor® EL (0.1% w/v) and Tween® 80 (0.05% w/v), PEG 
300 (20% w/v) was able to inhibit MDR1- Madin-Darby canine kidney (MDCK) cancer cells 
completely.  
Nanoparticles and liposomes are generally PEGylated to impart stealth properties to them29. 
Few PEGylated liposomes have been evaluated for their ability to overcome MDR too30,31. In 
one study19, pre-treatment of Caco-2 cells with surfactants composed of PEG and fatty acids/ 
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fatty alcohols led to enhanced  intracellular accumulation of epirubicin. In liposome-based 
studies which would be mentioned in subsequent sections of this review32,33,34, PEGylation 
seems to improve drug uptake in drug resistant cancer cells23. Increased tumor exposure by 
long circulating liposomes mimics continuous infusion31, imparts stealthiness and indeed PEG-
mediated MDR modulating abilities of nanocarriers would add another feather to their cap26. It 
would be interesting to mention here that many of the surfactants based MDR modulating 
excipients mentioned in the previous section have PEG as hydrophobic head group. Some of the 
PEG derivatives and analogues are enlisted in Table 1. 
 
Myrj® (polyoxyethylene 40 stearate)19 
Brij® (polyoxyethylene lauryl ether)35 
Peceol® (glycerylmonooleate) 20, 36 
Gelucire® 44/14 (lauroyl macrogol-32 glycerides) 20 
Labrasol® (caprylocaproyl macrogol-8 glycerides)37 
Cremophor® EL (glycerol polyethylene glycol ricinoleate)17 
Solutol® HS 15 (polyethylene glycol-15-hydroxystearate)38 
Polysorbates (Polyoxyethylenesorbitanfattyacidesters)21 
TPGS (D-alpha-tocopheryl-poly(ethylene glycol) 1000 succinate)39 
 
Table 1: PEG derivatives and analogues 
 
Most non-charged surfactants (Cremophor® EL, Solutol® HS 15, polysorbates and TPGS) exhibit a 
membrane anchoring hydrophobic tail and a hydrophilic headgroup. Seelig et al,40 reviewed 
that these head groups act as hydrogen bond acceptors as they are rich in ester and ether 
groups responsible for hydrogen bonding interactions between P-gp and surfactant.  Pluronics® 
(also known as poloxamers) are another set of polymeric pharmaceutical excipients which have 
been used as micellar nanocarriers for drug delivery41,42-43.  
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2.5.  Drug delivery systems  
Use of drug delivery systems (DDS) has shown considerable progress in past few decades 
especially with respect to cancer treatment. Nanoparticles (NPs) are proven to accumulate in 
tumor mass due to hyper-permeable vasculature and malfunctioning tumor lymphatic system 
without affecting healthy tissues; a phenomenon referred to as the ‘enhanced permeability and 
retention’ (EPR) effect 44. Nanocarriers in turn, offer promising drug delivery vehicles as they 
prevent recognition of drugs by the efflux transporters, readily endocytosed by drug resistant 
cells thereby improving intracellular drug accumulation. Different types of nanocarriers are 
established now such as nanoparticles, micelles, liposomes, nanogels and other self-assembled 
nanostructures (Fig. 2). These drug delivery systems can be fine-tuned by surface 
functionalization with ligands for active targeting45. Nanocarrier-based strategies to overcome 
cancer drug resistance have shown promising outcomes in the last decade46,47. 
 
Figure 2: Drug delivery systems such as nanoemulsion; liposome; polymer lipid hybrid NP; polymeric 
micelle; nanocapsule; hydrogels used to address multidrug resistance in cancer 
Most chemotherapeutic studies, on co-delivery of P-gp substrate together with P-gp inhibitors 
have failed at several stages in clinical trials. Several factors are responsible for these 
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therapeutic failures6. Due to expression of P-gp transporters at physiological barriers, inhibition 
of unrelated non-tumor cell P-gp transporters can compromise routine functions of body. For 
example, inhibition of P-gp transporters expressed at the blood-brain barrier (BBB) can cause 
neurological toxicity48. In such cases, decreased systemic clearance of anti-cancer drug has led 
to higher frequency of adverse effects associated with chemotherapy. Pharmacokinetic and 
pharmacodynamic interaction between MDR inhibitors and anti-cancer drugs are the most 
difficult to assess. In this scenario, the ability of nanoparticles to localize at tumor tissue (due to 
EPR effect) can reduce the level of exposure of inhibitors to non-target ABC transporters 
expressed at other physiological barriers. Inhibitors in soluble form are ineffective due to their 
low availability at tumor site which can be additionally addressed by delivering inhibitors via 
nanocarriers. Their sustained release at the tumor site can provide sufficient inhibition of ABC 
transporters to overcome drug resistance. 
On the other hand, inhibition of a specific transporter can be accompanied by inhibition of a 
non-target transporter. Tariquidar, a third generation inhibitor at a concentration of >100nM 
was shown to cross react with breast cancer resistance protein (BCRP) along with P-gp 
inhibition49. This has severe implications on healthy tissues such as intestine or BBB where BCRP 
expression plays protective roles. Action of biotransformation enzymes such as cytochrome 
P450 can also be compromised as certain P-gp inhibitors are substrate of cytochrome P450 as 
well 50. Delivery of inhibitors as nano-formulation has the potential to reduce such non-specific 
interactions causing unrelated pharmacological activities but more in vivo studies are required 
in this direction.  
Therapeutic DDS are promising alternative to conventional chemotherapeutic drug/ inhibitors. 
A number of features such as narrow size distribution, increased solubility and stability of drug 
molecule, high drug loading efficiency, controlled release, enhanced blood circulation time and 
feasibility to deliver multiple such therapeutic agents in single formulation have aided in 
targeting tumor cells, selectively delivering drug payload. Co-administration of anti-MDR and an 
anti-cancer drug in nanocarriers has demonstrated significantly enhanced cytotoxicity42. Several 
studies have established better pharmacokinetic profiles of the anti-MDR drugs when 
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administered in in vivo tumor models as compared to the animal group where the drug was 
administered in soluble form41,51.  
2.6. Categorization of nanocarriers on the basis of functionality 
Different combination therapies have been explored in order to overcome MDR (Fig. 3).  On the 
basis of research work in last few decades a pattern has emerged. The conventional 
chemotherapy co-administered with one of the three generations of MDR inhibitors (Fig.3a) for 
one, are yet to yield positive clinical outcomes in terms of overall survival and progression free 
survival. Scientists have been relentlessly working to develop drug delivery systems and 
combination treatments with sole aim to neutralize MDR-mediated drug efflux, built-up 
intracellular anti-cancer drug concentration and subsequently kill the tumor cell with minimum 
side effects in terms of toxicity and pharmacokinetic interactions on the body. A detailed case 
by case analysis of nano-based combination therapies is discussed to have a better overview of 
the most promising strategy that could be chalked out to overcome MDR in future. Inherent 
MDR modulating/ inhibiting nanocarriers form fourth category (Fig. 3e). 
i) P-gp substrate/ anti-cancer drug loaded nanocarrier co-administered with free MDR-
inhibitor (Fig.3b) 
ii) MDR-inhibitor encapsulated nanocarrier co-administered with free anti-cancer drug (Fig.3c) 
iii) Anti-cancer drug and MDR-inhibitor both co-encapsulated in the nanocarrier (Fig.3d) 
iv) Anti-cancer drug and/or P-gp inhibitor encapsulated in MDR-reversing nanocarriers (Fig. 3e) 
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Figure 3: Combination strategies of MDR inhibitor, anti-cancer drug and nanocarriers to circumvent 
multidrug resistance in cancer 
2.6.1. P-gp substrate/ anti-cancer drug loaded nanocarrier co-administered with 
free MDR-inhibitor (Fig.3b) 
In a pharmacokinetic study on male SD rats, self-microemulsifying drug delivery systems 
(SMEDDS)51 exhibited significant area under the curve above therapeutic level of paclitaxel as 
compared to the free paclitaxel wherein both groups were co-administered with free 
cyclosporin A. This enhanced systemic exposure of orally administered paclitaxel together with 
cyclosporin A was due to a diminished clearance and an increased uptake which enhanced oral 
bioavailability of paclitaxel.  
Likewise, Krishna et al, reported that doxorubicin-loaded liposomes can reduce anti-cancer 
drug-valspodar interactions leading to tumor growth inhibition in BDF1 mice with resistant 
lymphocytic leukemia (P388/ADR)52. Increased delivery of liposomal doxorubicin to tumor site, 
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alleviation of pharmacokinetic alterations and subsequent protection from toxicity 
exacerbation were associated with anti-tumor activity. When additional stealth properties were 
imparted to doxorubicin liposomes following PEGylation, an even higher tumor suppression 
were reported by the same group53. In human breast cancer tumor xenograft model 
(MDA435LCC6), sterically stabilized liposomes showed a further decrease in doxorubicin area 
under the curve circumventing pharmacokinetic interaction with soluble valspodar. 
This strategy, however, does not resolve the unfavorable pharmacological properties exhibited 
by MDR inhibitors administered in soluble form. Low availability of inhibitors at tumor tissue 
and ineffective inhibition of a specific transporter will ensue. This combination strategy does 
not rule out the possibility of unrelated pharmacological activity and will eventually lead to 
non-target transporter inhibition. 
2.6.2. MDR-inhibitor encapsulated nanocarrier co-administered with free anti-
cancer drug (Fig.3c) 
In order to avoid the pharmacokinetic interaction between anticancer drug and valspodar (PSC 
833), Lo et al,54,55 evaluated its inhibitory activity as free, liposomal and intralipid (o/w 
emulsion) formulations on the uptake and transport of epirubicin in Caco-2 cells and everted 
gut sacs of rats. It was observed that valspodar in free and liposomal formulations increased the 
apical to basolateral absorption of epirubicin in Caco-2 monolayers, thereby improving mucosal 
to serosal absorption of the drug in rat jejunum and ileum. However, valspodar loaded 
liposome achieved highest uptake of epirubicin at all studied concentrations in Caco-2 cells.  
In a similar work, Binkhathlan et al, studied pharmacokinetic interactions of valspodar 
encapsulated (PEO-b-PCL) micelles and doxorubicin in vivo56. Intravenous administration of free 
valspodar along with doxorubicin led to 50% reduction in clearance (CL) of the anti-cancer drug. 
On the other hand, micellar formulation of valspodar reduced doxorubicin CL by only 6%, as 
well as a significant increase in AUC and t½ of doxorubicin were observed. Hence, this strategy 
of using inhibitor-loaded nanocarriers and anti-cancer drug in solution form can considerably 
reduce the pharmacokinetic interactions between the two drug molecules. On the other hand, 
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due to higher doses of administered free anti-cancer drug, the undesirable toxic effects on 
healthy/ non-specific tissues cannot be ruled out. 
2.6.3. Anti-cancer drug and MDR-inhibitor both co-encapsulated in the nanocarrier 
(Fig.3d) 
A number of formulations co-delivering P-gp substrates and P-gp inhibitors under various 
categories have shown their ability to bypass drug efflux transporters. Some promising 
formulations in various DDS discussed subsequently include nanoparticle57, nanoemulsions58, 
liposomes59,60 and solid lipid nanoparticle42. The in vivo behavior of therapeutic agent/drug gets 
altered, following its encapsulation in nanocarriers and amongst other factors, depends on 
surface properties of the DDS rather than its own chemical structure. Most studies report 
reduced adverse effects and better therapeutic efficacy in comparison with non-targeted 
classical drug combination modalities used by clinicians61. 
2.6.4. Anti-cancer drug and/or P-gp inhibitor encapsulated in MDR-reversing 
nanocarriers (Fig. 3e) 
An interesting set of nanocarriers has emerged which have ingredients/ excipients/ polymers23 
to bypass MDR drug efflux that can inherently modulate MDR transporters without co-
administration or co-encapsulation of P-gp inhibitor. These nanopharmaceutical components of 
nanocarriers, fall under the category of ‘Generally Recognized As Safe’ (GRAS) substances 
approved by U.S. Food and Drug Administration22.  
Most routinely evaluated nanoparticles are developed using poly (lactide-co-glycolide) (PLGA) 
or poly(lactic acid) (PLA) as the polymer and poly(vinyl alcohol) (PVA) as the surfactant. As in 
most studies, NP carrying anticancer drug was not sufficient to overcome MDR until a sustained 
dose of P-gp inhibitors were maintained62. Thus, a novel strategy could involve replacing 
routinely used polymer/ surfactants/ stabilizers with active excipients which although inert, 
possess intrinsic P-gp modulating abilities63. In one study, replacing PVA with Pluronic® PF127 
as surfactants in doxorubicin loaded PLGA NPs led to higher toxicity and overcoming of cancer 
MDR64. In a number of studies reported in this review article, P-gp substrate/ anti-cancer drug 
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were encapsulated in various nanocarriers and tested for their anti-MDR efficacy in vitro and in 
vivo. These formulations and the active MDR-reversing component used in nanocarrier 
preparation are enlisted in Table 2. 
Formulation MDR-reversing agent P-gp substrate Reference 
Nanoparticle Vitamin E TPGS Paclitaxel Zhang65 
Nanoparticle Brij® 78 Paclitaxel Koziara66 
Solid Lipid NP Solutol® HS 15 Doxorubicin Kang67 
Lipid Nanocapsule Solutol® HS 15 Etoposide Lamprecht68 
Lipid Nanocapsule Solutol® HS 15 Paclitaxel Roger69 
Microgels Pluronic® P85 Doxorubicin Bromberg70 
Polymeric micelles Pluronic® P85 Doxorubicin Sharma41 
Amphiphilic micelles Vitamin E TPGS Rhodamine-123 Dabholkar43 
 
Table 2. Formulations studied for overcoming MDR in cancer, with the MDR-reversing component of 
nanocarriers and the P-gp substrate encapsulated. 
2.7. Nanocarrier system to overcome P-gp mediated drug efflux 
Case wise study of various formulations is done highlighting results on in vitro and in vivo 
cancer drug resistant cell lines and animal models. These different classes and subclasses of 
nanocarriers (Fig. 3) are discussed in relation to their advantages in overcoming multidrug 
resistance in cancer. Their beneficial roles could be ascribed to the inherent properties to 
bypass and modulate the P-gp efflux system or to the surfactants/ polymers which were 
employed to develop them. In all these studies, the association of a P-gp modulator or a P-gp 
substrate with a drug delivery system reduces the effective therapeutic dose thereby improving 
solubility, subsequent release and bioavailability of these agents at the pharmacological sites of 
action.  
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2.7.1. Nanoparticle 
Unlike aqueous core of liposomes, solid polymeric nanoparticles have been deployed to deliver 
hydrophobic therapeutic molecules. NPs are biodegradable, exhibit uniformity in size and shape 
and offer a controlled drug release profile over a period of time. Chavanpatil et al, studied 
effect of paclitaxel-loaded PLGA NPs and found them to be susceptible to P-gp mediated efflux 
on drug resistant breast cancer NCI-ADR/RES cells62. Resistance could be reversed with 
treatment of P-gp inhibitor verapamil but a sustained inhibition of P-gp was needed for 
therapeutic efficacy. The group later developed an AOT-alginate NPs (without inhibitor)to 
overcome resistance in MDR cells57. Aerosol OT (AOT) an anionic surfactant and sodium 
alginate, is a naturally occurring polysaccharide polymer used in DDS. Doxorubicin loaded AOT-
alginate NP demonstrated significant and sustained enhancement of drug-induced cytotoxicity 
in NCI-ADR/RES cells with an increase in the level of cellular and nuclear drug accumulation. An 
increase in the level of cellular accumulation was observed even with a mixture of blank AOT-
alginate NP and rhodamine. The results could also be translated in bovine brain microvessel 
endothelial cells (BBMECs) which are primary cells over-expressing P-gp. In a recent work, 
cyclosporine A coated-doxorubicin loaded PLGA NPs were able to improve the survival rates of 
A549 tumor bearing mice demonstrating the necessity to incorporate inhibitors within particles 
to achieve inhibition71. 
Nanoparticles of poly(lactide)–vitamin E TPGS (PLA–TPGS) copolymers were synthesized by a 
dialysis method72. D-alpha-tocopheryl-PEG 1000 succinate (TPGS) is a water-soluble derivative 
of natural vitamin E and is an effective emulsifier, pore-forming agent, absorption enhancer and 
bioavailability promoter39. PLA–TPGS NPs showed significant increase in the cellular uptake by 
1.8- and 1.4-fold as comparison to PLGA NPs cultured with HT-29 and Caco-2 cells, respectively. 
The IC50 of the PLA–TPGS NP formulation with HT-29 cells was found to be 40% lower than of 
Taxol® at the same dose of paclitaxel. In subsequent experiments, series of particles with 
varying PLA: TPGS ratios were evaluated65. It was observed that the PLA–TPGS NPs of 89:11 
PLA: TPGS ratio achieved the best effects on the cellular uptake and the cancer cell mortality of 
the drug-loaded PLA–TPGS NPs. In vivo evaluation in mice model, docetaxel-loaded vitamin E 
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TPGS-PLGA NP showed 284-fold efficacy (as compared to free drug) in formulations with 20% 
TPGS73. 
2.7.1.1. Lipid-based nanoparticles 
Lipid nanoparticles encapsulating paclitaxel, with emulsifying wax as the oil phase and 
polyoxyethylene 20-stearyl ether (Brij® 78) as the surfactant were developed66. These paclitaxel 
nanoparticles were able to overcome P-gp–mediated resistance in vitro in a human colon 
adenocarcinoma cell line (HCT-15) and showed 9 fold lower IC50 values in paclitaxel–NP treated 
group than Taxol® solution. Similar results were obtained in vivo in a nude mouse HCT-15 
xenograft model where paclitaxel NP group showed marked anti-cancer efficacy following 
intravenous injection.  
Paclitaxel and doxorubicin loaded lipid-based NPs were also developed by another group35. 
These drug loaded NPs containing the surfactant- Brij® 78 showed 6- to 9-fold reduction in IC50 
values in ovarian carcinoma NCI/ADR-RES and human melanoma cell line MDA-MB-
435/LCC6MDR1. They demonstrated increased uptake and prolonged retention of drug in all 
lipid-based NP formulations. Maximal efficacy was observed with paclitaxel NPs prepared with 
Miglyol® 812 in oil phase and TPGS and Brij® 78 as surfactants (PX BTM NPs). PEGylated PX BTM 
NPs significantly inhibited tumor growth in vivo in mice bearing resistant NCI/ADR-RES cell 
xenografts in comparison to all tested controls.  
While Koziara et al66 reasoned out enhanced delivery and anti-angiogenic effect as the factors 
overcoming MDR, Dong et al35 proved that the use of Brij® 78 for the preparation of 
microemulsion precursor was responsible for the same. Calceinacetoxymethylester and ATP 
assays confirmed that both free Brij® 78 and blank NPs inhibited P-gp and depleted ATP 
temporarily and reversibly. The change in the mitochondrial potential and mitochondrial 
swelling though transient were seen to be dominant only in MDR cells, indicating Brij® 78 and 
NP’s influence on the mitochondrial respiratory chain.  
Solid lipid nanoparticles (SLN) are lipid-based formulations with low toxicity, and have high 
partition for lipophilic drugs in the lipid phase. In one study, doxorubicin complexed with 
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soybean-oil-based anionic polymer and dispersed with lipid in water to form doxorubicin-
loaded solid lipid nanoparticles (Dox-SLNs)74. This SLN system led to significantly higher cellular 
doxorubicin uptake and retention by both human (MDR435/LCC6/MDR1) and murine 
(EMT6/AR1.0) P-gp-over-expressing breast cancer cell lines compared to doxorubicin solution 
treatment. An 8-fold increase in suppression of MDR 435/LCC6/MDR1 cell colony formation 
was also reported. The blank SLN and the excipients exhibited little cytotoxicity. Similar positive 
outcomes with Dox-SLNs were reported recently in two separate studies in in vivo cancer 
models67,75.  
Polymeric lipid nanocapsule (PLN), are modified SLN where anionic polymer is incorporated into 
lipids to complex the drug so as to increase its partition in the lipids. In another similar study, 
third generation P-gp inhibitor GG918 (elacridar) was co-administered with or without 
doxorubicin42. Dual loaded PLNs showed highest cytotoxicity, doxorubicin uptake by P-gp over-
expressing human breast cancer cell lines (MDR435/LCC6/MDR1) and long term suppression of 
cancer cell proliferation. On the other hand, administration of either component via PLN had 
least effect on cell death suggesting simultaneous delivery to same cellular location is critical in 
determining therapeutic efficacy of anticancer-chemosensitizer combination. 
2.7.1.2. Poloxamer-based nanoparticles 
Poloxamers also known by their trade names- pluronics are inert block co-polymers comprised 
of hydrophilic poly(ethylene oxide) (PEO) and hydrophobic poly(propylene oxide) (PPO) blocks 
arranged in an A-B-A tri-block structure: PEO-PPO-PEO76. Their surfactant properties allow them 
to self-assemble into micelles with a hydrophobic core and a hydrophilic shell at concentrations 
above CMC. MDR reversing activities of two of these block co-polymers- Pluronic® L61 and 
Pluronic® P85 were demonstrated using P-gp substrates- doxorubicin and daunorubicin 
respectively77,78. SP1049C which are mixed micelles of Pluronic® L61 and F127 incorporating 
doxorubicin have been extensively tested in vitro as well as in clinical trials with positive 
outcomes79. A combination of experiments examining the kinetics, concentration dependence, 
and directionality of P85 effects on P-gp-mediated efflux in bovine brain microvessel 
endothelial cells (BBMEC) showed that both energy depletion and membrane fluidization 
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(inhibiting P-gp ATPase activity) were critical factors contributing to the activity of the block 
copolymer80. SP1049C has demonstrated promising results in clinical trials in patients with 
advanced metastatic adenocarcinoma of the esophagus and gastroesophageal junction81 and 
has now been approved for chemoresistant gastric cancer82. 
Another block co-polymer, Pluronic® P85 was recently evaluated to assess its MDR preventive 
properties41. In vitro studies on murine lymphocytic leukemia cells (P388) cells and in vivo 
experiments on BDF1 mice bearing P388 ascite showed improved cytotoxicity when treated 
with doxorubicin/P85. Through various gene expressions profiling analysis, it was observed that 
apart from mdr1 gene, P85 abolished alterations of genes implicated in apoptosis, drug 
metabolism, stress response, molecular transport and tumorigenesis. Saxena et al83, have 
shown poloxamer 407/TPGS mixed micelles as a delivery system for gambogic acid(GA) to 
overcome MDR in cancer. Cytotoxicity of GA-loaded micelles was found to be 2.9 times higher 
in multidrug-resistant NCI/ADR-RES cells, and 1.6 times higher in MCF-7 cells, as compared to 
GA administered in free form.  
2.7.2. Amphiphilic micelles 
Polymeric particles are generally prepared by the self-assembling amphiphilic diblock 
copolymer-based strategy. Amphiphilic micelles of PEG2000-phosphatidyl ethanolamine (PEG-
PE)/ vitamin E TPGS solubilized with a P-gp substrate rhodamine-123 were developed making 
use of the P-gp altering properties of non-ionic surfactant TPGS43. The internalization of these 
micelles by Caco-2 cells, opposite to the internalization of the free rhodamine-123, was not 
influenced by the P-gp inhibitor verapamil, exhibiting a P-gp-independent micelle 
internalization. The study hence emphasized non-requirement for co-administration of P-gp 
inhibitors and that the use of a P-gp inhibitor is not necessary if the DDS is sufficient to bypass 
P-gp related drug efflux. 
Elamanchili et al84 prepared low molecular weight amphiphilic diblock co-polymer of 
methoxypolyethylene glycol-block-polycaprolactone (MePEG-b-PCL) for chemosensitization of 
MDR cancer cells. The studies of these polyether-polyester based co-polymer showed higher 
accumulation of P-gp substrates- rhodamine-123, doxorubicin and paclitaxel in Pgp over-
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expressing human ovarian cancer cell line NCI/ADR-RES, P-gp transfected canine kidney cell line 
MDCKII-MDR1 and parental cell line MDCKII but no influence on non P-gp expressing cells. 
Similar nanopreparation with dual functionality of paclitaxel-loaded MePEG-b-PCL micelles- 
delivering high doses of drugs and modulating P-gp were shown to be the reason for positive 
outcomes85. The reduction in accumulation of P-gp substrates in MDR cells at higher 
concentration of diblock co-polymer has been attributed to partitioning of the drug into 
micelles which decreases the free drug concentration available for uptake86.  
In order to improve solubility of valspodar and to aid its oral and intravenous administration in 
rats, methoxy-poly(ethylene oxide)-block-poly(e-caprolactone) (PEO-b-PCL) micelles were 
prepared87. These PEO-b-PCL formulations showed significant plasma area under the curve 
(AUC) and lower volume of distribution (Vdss) and clearance (CL). The study emphasized that 
the administration of a P-gp modulator in micellar form improves PK profile of the former and 
reduce the pharmacokinetic interactions with P-gp substrates and toxic profiles imposed by 
carrier such as Cremophor® EL. In vivo studies were subsequently done by the group in Sprague-
Dawley rats56. Doxorubicin was administered intravenously together with cyclosporine A/ 
valspodar as conventional or micellar formulation. Overall, encapsulation of valspodar in 
polymeric micelles was shown not just reduce their effects on the clearance of doxorubicin in 
rat but solved solubility issues of the highly hydrophobic derivative of cyclosporine A. 
2.7.3. Liposomes 
Liposomes are nanovesicles which are formed spontaneously when amphiphilic lipids are 
dispersed in water as an internal aqueous core surrounded by hydrophobic lipid layers. 
Consequently, hydrophilic drugs are encapsulated within core while lipid-soluble drugs organize 
within the lipid membrane. With the sole aim of overcoming MDR in cancer, few liposomal 
formulations have been studied. In another work, transferrin-conjugated liposomes co-
encapsulating doxorubicin and verapamil (Tf-L- DOX/VER) were developed and evaluated for 
their MDR reversal efficacy59 in doxorubicin resistant K562 cells (K562/DOX).Tf-L- DOX/VER 
showed 5.2 and 2.8 times greater cytotoxicity than non-targeted liposomes (L-DOX/VER) and Tf- 
targeted liposomes loaded with DOX alone (Tf-L-DOX) respectively. 
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Another doxorubicin and verapamil co-loaded liposomes was tested for in vitro cytotoxicity on 
MDR rat prostate adenocarcinoma Mat-LyLu-B2 (MLLB2) cell lines60. The toxicity of relevant 
formulations were in the following order: doxorubicin/ verapamil co-encapsulated stealth 
liposomes (DARSL’s) (0.0079 µM) > doxorubicin liposomes and verapamil liposomes (0.0099 
µM) > doxorubicin liposomes with free verapamil (0.96 µM). The in vivo results88 clearly 
demarcated doxorubicin clearance when administered (as liposomes) with verapamil either 
free or co-encapsulated, as against free administration of both molecules. The DARSL’s 
treatment resulted in lowered doxorubicin distribution in heart, kidney, liver and lungs. Co-
encapsulation of third generation P-gp inhibitor tariquidar together with paclitaxel in stealth 
liposomes has also shown promising in vivo results33. Treatment to human ovarian 
adenocarcinoma SKOV3TR cells led to enhanced cytotoxicity at a paclitaxel dose, which was 
ineffective in absence of tariquidar, implying significant reversal of MDR towards paclitaxel. In 
MDR promyelocytic leukemia-HL60 xenograft mice, gradual shrinkage of tumor was reported 
when treated with stealth liposomes co-encapsulating topotecan and amlodipine34. 
2.7.4. Lipid-based formulations 
2.7.4.1. Nanoemulsion 
Nanoemulsion refers to heterogenous mixtures of oil-in-water using high energy emulsification 
methods, where oil droplets are in the range of 20-200nm. Paclitaxel-nanoemulsion were 
developed to enhance the oral bioavailability of the anti-cancer drug: comprised of pine nut oil 
as internal oil phase, egg lecithin as primary emulsifier and water as the external phase89. They 
further developed nanoemulsion by co-encapsulating paclitaxel and curcumin58. Western blot 
results showed decrease in P-gp expression of ovarian adenocarcinoma MDR phenotype 
SKOV3TR cells that explained 1.8 fold reductions in IC50 values of nanoemulsions as compared 
to those with paclitaxel alone. 
2.7.4.2. Lipid Nanocapsules 
Lipid nanocapsules (LNC) refer to DDS whose structure is a hybrid between polymeric 
nanocapsules and liposomes90. They have an oily core surrounded by a tensioactive rigid 
membrane. Cytotoxic drug- etoposide loaded LNC showed higher efficiency than the drug 
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solution on glioma cells, while blank LNCs were found to be less inhibitory than the pure drug at 
equivalent concentrations. In a similar work, paclitaxel-loaded LNCs were shown to reduce the 
survival of 9L and F98 cells significantly in comparison to free Taxol® treatment. LNCs greatly 
reduced tumor mass in in vivo F98 subcutaneous glioma mice model. This study demonstrated 
that the inhibition of MDR efflux pumps could be due to its interaction with released free 
intracellular Solutol® HS-15 (an LNC component) and redistribution of intracellular cholesterol. 
Solutol® HS 15, a non-ionic surfactant has been proved to exhibit P-gp inhibitory activity91. Lipid 
nanocapsules have also led to improved gastrointestinal crossing of paclitaxel in Caco-2 cells via 
transcytosis69. 
2.7.5. Self-emulsifying  drug delivery systems 
Self-emusifying drug delivery systems (SEDDS) are isotropic mixtures of oils and surfactants 
which can then disperse in gastrointestinal lumen forming microemulsions. They can readily 
enhance the oral bioavailability and hence absorption of lipophilic drugs92. Use of such self-
microemulsifying drug delivery systems (SMEDDS) comprised of vitamin E in oil phase and 
deoxycholic acid sodium salt, TPGS and cremophor RH 40 as surfactants has been evaluated51. 
The aim was to increase solubility of paclitaxel and evaluate efficacy of formulation when 
delivered paclitaxel with or without P-gp inhibitor, cyclosporine A. Compared to Taxol®, the oral 
bioavailability of paclitaxel SMEDDS increased by 28.6% to 52.7% at various doses. Following 
co-administration with cyclosporine A, paclitaxel SMEDDS showed a higher bioavailability and 
much longer retention time above the therapeutic level than Taxol® alone. Thus, significant 
improvement in paclitaxel absorption could be attributed to the combination of P-gp inhibiting 
lipidic excipients together with specific P-gp inhibiting drug93.  
2.7.6. Gels 
Gel refers to cross-linked hydrophilic and/or hydrophobic polymer network that spans the 
volume of liquid medium. Their extraordinary swelling and de-swelling ability upon external 
stimulation such as pH, temperature etc., have found their usage in selective drug delivery 
applications amongst others. They can adsorb large quantities of drugs and biomolecules 
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(enzymes/ growth factors etc.) within their three-dimensional mesh-like structures, acting as 
reservoirs and releasing their cargo in a controlled fashion over a period of time.  
2.7.6.1. Nanogel 
NanoGelTM are synthesized by cross-linking cationic (polyethyleneimine (PEI)) with non-ionic 
(carbonyldiimidazole-activated (PEG)) polymer using emulsification/solvent evaporation 
technique. NanoGelTM immobilized with anti-sense phosphorothioate oligonucleotides (SODN)- 
specific to human mdr1 gene94 demonstrated efficient transport across polarized monolayers of 
human intestinal epithelial cells (Caco-2) was demonstrated.  
Another nanogel formulated by the same group was prepared by complexing fludarabine-PEI in 
the core surrounded by hydrophilic polyethylene glycol (PEG) envelope95. For increased 
internalization folate molecules were attached to the nanogels.  An enhanced cytotoxicity 
towards MCF-7 was observed and transcellular transport of the folate-nanogel polyplexes was 
found to be 4 times more effective compared to the drug alone. The results showed better 
tumor specificity and significantly reduced systemic toxicity.  
2.7.6.2.  Hydrogel 
Hydrogels are hydrophilic, three-dimensional networks which can imbibe large amounts of 
therapeutic agents96. Biodegradable hydrogels based on N-(2-hydroxypropyl) methacrylamide 
(HPMA) were able to maintain sufficient therapeutic concentrations of drug with minimal side 
effects. On subcutaneous implantation, release of doxorubicin, was observed up to 96 hours. In 
contrast to application of doxorubicin alone, a cocktail of doxorubicin with cyclosporine A 
blocked the proliferation of P-gp-over-expressing Bcl1 leukemia MDR cell lines in vitro by 
inducing apoptosis97. Promising results were obtained in mice with advanced Bcl1 leukemia as 
well. 
2.8. Perspective and future challenges 
In spite of three generations of MDR inhibitors, few positive clinical outcomes have been 
obtained till date. This review discusses several formulation strategies with relevant recent 
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examples that have resulted in: 1) increased cytotoxicity to drug resistant tumor cells in 
comparison to the treatment with either entity alone, 2) prolonged release of encapsulated 
drug/ inhibitor which leads to a sustained sensitization of resistant cells facilitating tumor cell 
killing by overcoming MDR, and 3) reduced systemic pharmacokinetic interactions between 
cytotoxic drug and MDR inhibitor.  
Lipid composition of cell membrane and their interaction with drug molecules are attributed for 
low drug accumulation in MDR cells. Drug resistant cells differ in their biophysical 
characteristics in comparison to their parental counterparts. They are much rigid due to the 
presence of higher amount of phospholipids and saturated fatty acids in turn affecting 
endocytosis process; making the membranes thick and contributing to their barrier function. 
This in turn traps the hydrophobic anticancer drugs/ MDR substrates which get confined to the 
lipid bilayer before finally getting effluxed by MDR transporters. On the other hand, in sensitive 
cells hydrophobic drug gets transported inside the cell due to the more fluid cell membrane. 
Therefore, biophysical characteristics of cell membrane can aid towards a better understanding 
of nanocarrier-lipid bilayer interactions and more efficient mode of drug delivery to address 
cancer drug resistance. 
Nanocarriers not only act as vehicle, they aid in accumulation of drug/ inhibitor within tumor 
mass which is difficult to achieve using their soluble counterparts. This tumor localization can 
overcome the issues of low availability at the tumor tissue and unrelated pharmacokinetic 
activity as observed with MDR inhibitors in several clinical outcomes. Moreover, a sustained 
release of cargo ensures prolonged drug delivery and sensitization of drug resistant tumors by 
achieving sub-optimal concentrations of therapeutic molecules. Further fine-tuning of 
nanocarriers is underway, to endow them with intrinsic MDR-modulating abilities. 
Certain excipients/ polymers routinely used in pharmaceutical industries as well as in the 
preparation of nanocarriers-such as surfactants, pluronics®, PEG derivatives and analogues, 
amphiphilic diblock copolymers etc., are known to exhibit inherent MDR-reversing abilities. 
These excipients are mostly biodegradable, have safe pharmacokinetic profile, improve drug 
solubility and lead to an enhanced absorption as compared to the free drug. They are not 
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absorbed by the intestine and have been carefully studied to be safe to use in different class of 
formulations like liposomes, solid-lipid nanoparticles or polymeric micelles. When DDS are 
developed using these `surface active agents`, the surface property enables the carrier system 
itself to modulate ABC transporters and overcome MDR.  
These compounds exhibit MDR-modulatory abilities at very low concentrations which are far-
less than their clinical applications and have been approved by drug regulatory authorities for 
varied pharmaceutical applications; further in-depth characterization would be required to 
elucidate their mode of action and their interaction with plasma membranes- as nanocarriers 
and in free form. In some cases, free surfactant units released from nanocarriers can form 
micelles and entrap the co-administered hydrophobic MDR substrates which get trapped at the 
rigid drug resistant cell membrane reducing the efficacy of treatment. On the other hand, free 
surfactant units released intracellularly following nanocarrier-membrane interactions can also 
lead to MDR inhibition by redistributing intracellular cholesterol. Much effort should also be 
given to optimize the concentration to be used in surfactant-based nanocarrier formulation. 
Mechanism of bypassing P-gp efflux for some of the ‘surface active’ excipients has been 
proposed to involve fluidization of lipid membrane or rigidization of lipid bilayer which could be 
co-related to their ability to influence nanoparticle-biophysical interactions with cell membrane 
lipids. Poloxamers are the most characterized in terms of understanding their MDR modulatory 
mechanisms. A detailed evaluation of mode of action of ‘surface active agents’ to overcome 
MDR would be desirable for better understanding of the molecular dynamics at cellular level 
and to avoid undesirable systemic pharmacokinetic interactions.  
However, as a word of caution formulations that yield positive outcomes must be subjected to 
a thorough molecular assessment in order to understand the underlying mechanism of MDR 
inhibition. In vitro cell culture models must always involve a drug resistant and its parental 
‘sensitive’ cell line to see therapeutic advantage following treatment. Benefits in terms of 
resistance ratio- which is the quotient of IC50 of treatment group in resistant cell line to that of 
untreated parental cell line, should also be reported. Characterization of cells in terms of 
assessing the expression profile of MDR transporter/s must be developed as a laboratory 
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practice. Similar studies should be conducted in relevant animal models in order to extrapolate 
results obtained in vitro.  
Based on these results, novel set of nanocarriers have emerged. Formulations with ‘surface 
active’ properties loaded with both anti-cancer drug and P-gp inhibitor could be considered 
more viable option for overcoming MDR. The synergistic effects of P-gp inhibitor and P-gp efflux 
bypassing nanocarrier system can work as a ‘dual strategy’ which would lead to delivery of anti-
cancer drug within the tumor cell, building up cytotoxic drug concentrations to the levels that 
can kill the target cell. Although, a detailed in vivo characterization of these ‘inert’ components 
needs to be done, the current set of results seems promising and can be recommended for 
their usage in formulating nanocarriers for their MDR reversing potentials. Simultaneously, 
MDR reversing surface ‘active’ nanocarriers should be evaluated and further explored so as to 
enable their clinical translatability.  
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3.1. Abstract 
Several pharmaceutical excipients are known for their ability to interact with cell membrane 
lipids and reverse the phenomenon of multidrug resistance (MDR) in cancer. Interestingly, 
many excipients act as stabilizers and are key ingredients in a variety of nano-formulations. In 
this study, representatives of ionic and non-ionic excipients were used as ‘surface active agents‘ 
in nanoparticle (NP) formulations to utilize their MDR reversing potential. In-vitro assays were 
performed to elucidate particle-cell interaction and accumulation of P-glycoprotein substrates-
rhodamine-123 and calcein AM, in highly drug resistant glioma cell lines. Chemosensitization 
achieved using NPs and their equivalent dose of free excipients was assessed with the co-
administered anti-cancer drug- doxorubicin. Amongst the excipients used, non-ionic surfactant- 
Cremophor® EL, and cationic surfactant- cetyltrimethylammonuium bromide (CTAB) 
demonstrated highest P-gp modulatory activity in both free solution form (upto 7-fold lower 
IC50) and as a formulation (up to 4.7-fold lower IC50) as compared to doxorubicin treatment 
alone. Solutol® HS15 and Tween® 80 exhibited considerable chemosensitization as free solution 
but not when incorporated into a formulation. Sodium dodecyl sulphate (SDS)-based 
nanocarriers resulted in slightly improved cytotoxicity. Overall, the results highlight and 
envisages the usage of excipient in nano-formulations in a bid to improve chemosensitization of 
drug resistant cancer cells towards anti-cancer drugs. 
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3.2. Introduction 
Among several efflux transporters, P-glycoprotein (P-gp), has garnered enormous attention in 
cancer research as well as drug delivery. It is a multidrug resistance protein of the ATP-binding 
cassette (ABC) family of efflux transporters1. ATP-dependent drug efflux leads to reduced 
effective cellular concentrations of anti-cancer drugs. In addition to being expressed in tumor 
cells, P-gp expression normally occurs in cells of kidney, breast, brain, colon, liver and pancreas. 
Consequently in cancer models of these tissues, their over-expression leads to MDR.  
P-gp inhibitors developed over the years have proved disappointing in most of the clinical trials 
due to unpredictable pharmacokinetic interactions with co-administered anti-cancer drug and 
inherent inhibitor toxicity leading to toxic plasma concentrations and side effects in patients2. 
Nano-formulations carrying anti-cancer drugs, on the contrary, can revert drug resistance with 
minimal interference in the pharmacokinetic profile of the drug and a more localized action 
within tumor tissue. Different drug delivery systems such as nanoparticles (NPs) or liposomes 
etc., have shown promise in their ability to bypass P-gp mediated drug efflux, enhance cellular 
uptake, increase intracellular concentration of co-administered anti-cancer drug, exhibit 
minimal inherent toxicity compared to the inhibitors and act as a reservoir for both inhibitors 
and anti-cancer drugs for a sustained therapeutic outcome3.  
Several excipients routinely used in pharmaceutical industry as drug solubilizers and stabilizers 
in various formulations are known for their ability to reverse P-gp mediated drug efflux. These 
belong to classes as diverse as polymers (polyethylene glycol (PEG)), lipids (peceol), 
excipients/surfactants (Cremophor® EL, SDS) and are derived from natural or synthetic 
sources4,5. Non-ionic surfactants including Cremophor® EL, polysorbate 80 (Tween® 80) and 
Solutol® HS15 have been extensively evaluated6 for their P-gp inhibitory ability in P-gp over-
expressing Caco-2 cell monolayers7 and everted gut sac model8.  Recently, Cremophor® EL and 
Tween® 80 were shown to inhibit another significant MDR transporter- multidrug resistance 
protein (MRP2) more efficiently than P-gp9 exhibiting dual P-gp-MRP2 inhibition capability.  
Few studies are coming to fore, wherein excipient with MDR modulatory properties when 
incorporated in nanocarriers mediate drug resistance reversal in cancer. Lipid nanocapsules 
(LNC)10,11 and solid lipid NP (SLN)12 developed recently used Solutol® HS15 in their preparation. 
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Nanohybrid liposomes- incorporating Solutol® HS15, Pluronic® F68 and Cremophor® EL, were 
reported to show positive results in paclitaxel resistant lung carcinoma cell lines13. However, a 
comparative study with non-ionic, cationic and anionic surfactants incorporated polymeric NPs 
is lacking in this regard. 
In this work, we conceptualize that when ‘surface active agents’ are incorporated in NP, they 
get immobilized on the surface of nanocarriers, behaving as P-gp efflux pump modulator as 
soon as they come in contact with tumor cell. This possibly enables bypassing/ modulating P-gp 
transporter proteins by different mechanisms on the cellular membrane14.  
Poly lactic-co-glycolic acid (PLGA) based polymeric NPs were prepared by solvent evaporation 
method with different surfactant combinations. In addition to non-ionic surfactants 
(Cremophor® EL, Solutol® HS15 and Tween® 80), SDS (anionic) and CTAB (cationic) were 
included in the present study to compare the effect of surface charge of nanocarrier on P-gp 
inhibition and the possible cell-nanocarrier interaction. Cell adhesion, P-gp inhibitory abilities 
and cytotoxicity of the particles co-administered with anti-cancer drug doxorubicin were 
evaluated and compared in this work. 
 
3.3. Materials and methods 
3.3.1. Materials 
Polyvinyl alcohol (Mowiol 4-88) and PLGA resomer502H were kind gift from Kuraray (Frankfurt, 
Germany) and Evonik®(Darmstadt, Germany) respectively. SDS was obtained from Carl Roth 
(Karlsruhe, Germany) while Cremophor® EL and CTAB were provided by Fluka Analytical. 
Polyethylene glycol-660 hydroxystearate (PEG-HS, Solutol® HS15) and Tween® were obtained 
from BASF AG (Ludwigshafen, Germany) and Caelo (Hilden, Germany) respectively. Rhodamine-
123, calcein acetoxymethylester (calcein AM), wheat germ agglutinin-FITC, doxorubicin 
hydrochloride, 3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2-tetrazolium bromide (MTT), nile red 
and all other solvents and reagents were purchased from Sigma Aldrich (Steinheim, Germany) 
and were of analytical grade. FITC-conjugated secondary antibody and glycoprotein-P 
monoclonal antibody (C219) were obtained from Biozol (Eching, Germany) and Thermo 
Scientific (Rockford, USA) respectively. 
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3.3.2. Cell lines 
Glioma cell lines of F98 (glioblastoma) and 9L (gliosarcoma) were obtained from ATCC 
(Manassas, VA, USA). The cell-lines were passaged in T-75 tissue culture flasks in Dulbecco’s 
Modified Eagle Medium (DMEM) supplemented with 10% fetal calf serum (FCS), 100 U/mL 
penicillin and 0.1 mg/mL streptomycin in a humidified 37°C incubator with 5% CO2. All cell 
culture grade chemicals were purchased from Sigma Aldrich. Passages between 5 and 30 were 
used for the experiments.  
 
3.3.3. Preparation and characterization of nanoparticles 
PLGA nanoparticles were prepared by solvent evaporation method using an o/w emulsion 
solvent evaporation process. The organic phase comprised of 20mg PLGA dissolved in 400µL 
ethyl acetate prior to all the preparation steps. The aqueous phase was prepared with 2mL of 
various surfactants- PVA, PVA with SDS, Cremophor® EL, CTAB, Solutol® HS15 and Tween® 80 at 
different concentrations (Table 1). The organic phase was emulsified with the aqueous phase 
(50% duty cycle for 4 min) by sonication using a microtip probe sonicator (Bandelin Sonoplus, 
Germany) in an ice bath. The organic mixture was then removed under reduced pressure for 20 
min. This was followed by centrifugation at 12,000 rpm for 20 min at 6°C (Universal 320 R 
Hettich Cetrifuge, Tuttlingen Germany) to remove excess surfactants from NPs. Nile red 
particles (NR-NP) were similarly prepared by adding 40µL of 0.1% nile red solution in the 
organic phase. The nanoparticles were analyzed for their size distribution, polydispersity index 
(PDI) and zeta potential using a ZetaPlus (Brookhaven Instrument Corporation) (Table 1). Each 
sample was analyzed in triplicate. 
 
3.3.4. P-gp expression analysis 
For sample preparation of cells for flow cytometry, cells were trypsinized, counted and 
centrifuged. Aliquots of 0.5 million cells per sample were re-suspended in 50µL PBS and 
incubated with C219 primary antibody for 15 min in dark at 4°C. Cells were washed twice with 
FACS buffer (PBS, heat inactivated FCS (1%), sodium azide (0.09%)). Further incubation with 
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secondary antibody was done as aforementioned with primary antibody.  Cells were washed 
again and re-suspended in FACS buffer. All measurements were made on a BD FACSCantoII (BD 
Biosciences, San Jose, CA) flow cytometer. Appropriate controls were used for both cell lines. 
 
3.3.5. In-vitro cytotoxicity 
Approximately 5,000 cells per well were seeded in 96-well plates and grown in DMEM 
overnight. Cells were then incubated with the different nanoparticle preparations of equivalent 
polymer concentrations (500- 0.5µg/mL) for 24 hr. After carefully removing the supernatant 
followed by two washing steps in PBS (pH 7.4), cells were further incubated with the MTT 
(5mg/mL). The cells were then lysed and MTT crystals dissolved in dimethyl sulfoxide. The plate 
was read at 544nm using a plate reader (Victor 3, Perkin Elmer). The cell viability was calculated 
using an untreated control as reference. For evaluating the chemosensitization of cells, both 
excipient-based NPs and their equivalent excipient concentrations in solution form were tested. 
MTT was performed together with increasing doxorubicin concentrations following same 
protocol at a particle concentration of 50µg/mL. Control experiments were performed with 
medium containing 10% (v/v) DMSO. 
 
3.3.6. Nile red cell adhesion assay 
5,000 cells were plated per well in 96-well plate and incubated overnight for adherence. After 
removing supernatant, treatment was given with NR-NPs encapsulating 0.5µg/mL equivalent 
nile red. After 4 and 24 hr incubation, cells were washed once with ice-cold PBS followed by 
addition of 100 µL ethanol solution per well. The absorbance was measured at (544 nm/ 615 
nm) with a plate reader (Victor 3, Perkin Elmer). 
 
3.3.7. Calcein AM accumulation assay 
For determining the effect of nanoparticles on P-gp inhibition, a calcein AM accumulation assay 
was performed as described elsewhere15 with small modifications. Following trypsization and 
centrifugation of glioma cells and repeated washing steps with Krebs-Hepes buffer (KHB), cells 
were seeded into black 96-well plates (Greiner, Frickenhausen, Germany) at a density of 
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approximately 20,000 cells per well to which 50µg/mL NP was added. After a 30 min pre-
incubation period, 2.5 µM calcein AM solution was added to each well. The fluorescence was 
measured immediately in constant time intervals (60 s) up to 240 min at an excitation 
wavelength of 485 nm and an emission wavelength of 520 nm with a BMG POLARstar 
microplate reader maintained at 37°C. 
3.3.8. Rhodamine-123 uptake assay 
To re-evaluate the effect of inhibitors on P-gp, a rhodamine-123 accumulation assay was 
performed as it is a known P-gp substrate. 5,000 cells each of F98 and 9L were seeded in 96-
well plates and incubated overnight for adherence. Rhodamine-123 (0.3µM) together with 
50µg/mL NP treatment was given. Following incubation for 1 and 4hr, media was removed, and 
wells washed once with PBS. 100µL Triton-X 100 (1% v/v) was added to each well and incubated 
for 30min to lyse cells and extract rhodamine-123. The fluorescence was measured at an 
excitation wavelength of 505 nm and an emission wavelength of 540 nm with a fluorescence 
spectrophotometer (Victor3, Perkin Elmer) and normalized for cellular protein levels as 
determined by bicinchoninic acid (BCA) assay. 
3.3.9. Statistical Analysis 
All the experiments were performed in triplicates and reported as mean ± S.D. Statistical 
comparisons were made with one-way ANOVA followed by Dunnett’s post test using GraphPad 
Prism software version 5.0. In all cases, p<0.05 was considered to be significant at 95% 
confidence level. 
 
3.4. Results 
3.4.1. Physicochemical characterization 
Table 1 shows the respective surfactant concentration used for particle preparation and their 
corresponding size, polydispersity indices (PDI) and zeta potential. PVA NPs (115 ± 15 nm) had 
smallest size of all NPs and there was a slight increase in particle size on addition of anionic 
surfactant SDS in PVA+SDS NPs (133 ± 8 nm). This could be due to the self-assembling property 
of anionic surfactants being altered by the non-ionic surfactant PVA forming more stable NPs. 
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On the other hand, the addition of cationic and non-ionic surfactants with long hydrophilic 
chains led to bigger particles. Solutol® HS15 NPs exhibited largest size (267 ± 7 nm) which was 
accompanied by a slight increase in PDI value (0.16). 
Zeta potential of particles varied clearly showing the effect of surfactant on surface properties 
of nanocarriers. CTAB NP’s demonstrated a cationic character while the other surfactants 
exhibited negative surface charges which could be explained due to their inherent charge 
properties and the use of anionic PLGA as the polymer. 
Two sets of cytotoxicity assays were performed. To assess the toxicity exhibited by different 
NPs against gliomas, MTT assays were performed for 24 hours with varying NP concentrations. 
Results were reported as LC50 (lethal concentration, 50%) of NPs (Table 1). Except CTAB NPs, 
none of the formulations were cytotoxic up to 500µg/mL NP concentration. CTAB particles 
showed slightly higher toxicity (LC50- 199 ± 80.3µg/mL) in F98 cells than the more resistant 9L 
cells (LC50- 312 ± 24µg/mL). In all subsequent in vitro assays a NP concentration of 50µg/mL was 
used. MTT results with doxorubicin are explained in section 3.6. 
 
 Concentration 
(g/100mL) 
Size 
(nm) 
Zeta potential 
(mV) 
PDI LC50 (µg/mL) 
F98 9L 
PVA 1 115.07 
(± 15.55) 
-13.07 
(± 0.98) 
0.10 
(± 0.03) 
>500 >500 
SDS+PVA 0.05 133.43 
(± 8.55) 
-17.27 
(± 4.48) 
0.10 
(± 0.04) 
>500 >500 
Cremophor® EL 0.2 224.6 
(± 2.25) 
-13.35 
(± 0.99) 
0.10 
(± 0.01) 
>500 >500 
CTAB 0.02 239.93 
(± 1.16) 
6.02 
(± 2.61) 
0.11 
(± 0.04) 
199  
(± 80.3) 
314 
(± 24) 
Solutol® HS 15 0.1 267.57 
(± 7.54) 
-13.26 
(± 2.15) 
0.16 
(± 0.02) 
>500 >500 
Tween® 80 1 180 
(± 2.96) 
-18.24 
(± 0.78) 
0.11 
(± 0.00) 
>500 >500 
 
Table 1: Physicochemical characterization of nanoparticles prepared with different surfactants. The 
hydrodynamic diameter, polydispersity index (PDI) and zeta potential was analyzed by PCS. LC50 values 
of all NP formulations following their incubation with F98 and 9L cells for 24h. (Mean ± SD; n=6). 
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3.4.2. Protein expression analysis 
Gliomas were used in the current study as they represent the most malicious and aggressive 
cancers of all16. To demonstrate the magnitude of expression of P-glycoprotein, P-glycoprotein 
surface expression was examined in both F98 and 9L cells using the monoclonal antibody C219 
which recognizes the COOH-terminal cytoplasmic sequence of P-glycoprotein isoforms. 
Although F98 cells are known to over-express P-gp, in 9L cells, their expression was found to be 
more than in F98 (Fig.1) ascribing an even higher resistant character to 9L cell lines than F98.  
 
Figure 1. Histogram of P-gp expression in F98 glioblastoma (white) and 9L gliosarcoma (grey) cell lines.  
 
3.4.3. Cell adhesion studies 
To understand the interaction between cells and particles, NR-NP with all surfactants were 
prepared and cells treated for 4 and 24hr. These time points were chosen because in-vitro 
accumulation and cytotoxicity assays were performed within these time-frames respectively. At 
4hr, only Cremophor® EL NR-NP demonstrated significant adherence in comparison with free 
nile red solution in both cells (Figure 2a). 24hr post-treatment showed slightly higher adherence 
of NR-NPs in both cell lines than 4hr treatment (Figure 2b). However, this increase was 
significant with Cremophor® EL and CTAB NR-NPs in both cell lines and PVS+SDS nile red NPs in 
F98 cell line. Thus, the interaction between NPs and cells appeared to be surfactant and cell 
type-dependent.  
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Fig. 2. Cell-associated particles after incubation with F98 and 9L cells for 4hr and 24hr at a concentration 
of 0.5µg/mL equivalent nile red. The interaction was quantified by determination of fluorescence 
intensity following nile red extraction with ethanol. (Mean ± SD; n=6). One-way ANOVA followed by 
Dunnett’s post test; Fig.2a. 4hr *p < 0.01 and δp < 0.01 compared with nile red solution. Fig. 2b. 24hr *p 
< 0.01 and δp < 0.01 compared with nile red solution. 
 
3.4.4. Calcein AM assay 
The ability of NPs to modulate P-gp function was evaluated using calcein AM assay in both P-gp 
expressing cells. Following diffusion, calcein AM gets hydrolyzed by esterases present in cells to 
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calcein anion which is fluorescent and hydrophilic. In P-gp over-expressing cells, increased 
fluorescence of intracellular calcein is measured as a function of P-gp inhibition.  The results 
(Figure 3) represent rate of accumulation of calcein within cells. As can be observed, the results 
showed a significant rate of calcein accumulation in Cremophor® EL and CTAB NPs in both (9L 
and F98) and PVA+SDS NPs in F98 cell lines in comparison to control (C-AM without any 
treatment). The decrease in calcein level in Solutol® HS15 treated NPs was an exception as the 
accumulation rate was much slower than with free calcein levels. One possible explanation 
could be the entrapment of the fluorescent dye into the micelles formed following the 
detachment of loosely bound Solutol® HS15 molecules on NP surface. These micelles tend to 
get entrapped in the membrane resulting in loss of interaction with the P-gp transporter 
protein9,13. 
 
 
Figure 3. Calcein AM accumulation assay after incubation with particles (50µg/mL NP suspension) for 
3hr. (Mean ± SD; n=6). ; *p < 0.05 and δp < 0.05 compared to calcein AM accumulation (without NP) in 
F98 and 9L cells respectively, One-way ANOVA followed by Dunnet‘s post test. 
 
3.4.5. Rhodamine-123 uptake assay 
Rhodamine-123, a P-gp substrate and fluorescent dye is routinely used to study the MDR 
phenomenon. Rhodamine-123 uptake increased in all treatment groups including control group 
(rhodamine-123 solution) and was markedly enhanced after the 4hr treatment in comparison 
  3. Chapter 1 
 
47 
 
to the 1hr treatment (Figure 3). Excipient-based NPs appeared to facilitate the dye uptake by 
sensitizing the efflux transporter function in both resistant cell lines.  Accumulation was 
significantly high in CTAB, Cremophor® EL and PVA+SDS NPs in both cell lines by 4 hours. In F98 
cells, which are comparatively less resistant, almost all particle preparations sensitized the cells 
leading to enhanced substrate accumulation except for Solutol® HS 15 NPs. Rhodamine-123 
binds strongly (Kd=2µM) to serum proteins present in cell culture media17; consequently, as the 
uptake experiments were done in serum-free media, a 24-hour study was not feasible.  
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Figure 4. Rhodamine-123 accumulation was evaluated following treatment with NP’s prepared with 
different surfactants for 1 and 4hr in A. F98 and B. 9L glioma cells. (Mean ± SD; n=9). *p<0.001and 
#
p<0.001 compared to rhodamine-123 accumulation (without NP) in both cells, One-way ANOVA 
followed by Bonferroni Multiple comparison post test.  
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3.4.6. Cytotoxicity studies 
As seen from MTT assay results (Figure 5), gliosarcoma 9L cell line appeared to be less sensitive 
to doxorubicin than F98. Following 24hr chemosensitization of cells with different NP 
formulations and their corresponding excipients, Cremophor® EL and CTAB appeared to 
modulate MDR transporter function the most. As compared to control (treatment with 
doxorubicin), Cremophor EL and CTAB treatment (both NPs and their equivalent surfactant 
dose) resulted in lower IC50 values (Table 2).  
PVA and Solutol® HS15-based NPs did not appear to show any significant reversal although free 
Solutol® HS15 led to approximately 3-fold lower IC50 values in both cell line. In substrate 
accumulation experiments, similar observations were made. In comparison to doxorubicin and 
SDS treated group, PVA+SDS NPs showed lower IC50 in both cells which was an extrapolation of 
previous results as well. In general, NPs (Figure 5. white bars) exhibited higher IC50 values than 
their corresponding excipient component (Figure 5. black bars). 
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Figure 5. IC50 values of doxorubicin in F98 and 9L cell lines following NP treatment (white bars) and 
equivalent excipient concentrations (black bars) for 24h (Mean ± SD; n=3). *p< 0.05 and #p< 0.05 
compared with doxorubicin solution. 
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3.5. Discussion 
FDA approved excipients/ surfactants have found regular use as coatings and solubility 
enhancers in pharmaceutical industry. Many excipients, though not inherent MDR inhibitors, 
have shown P-gp modulatory function and sensitize resistant cells to MDR substrates. In this 
study, non-ionic and ionic nanoparticles were developed and assessed in highly resistant glioma 
cell lines for their ability to overcome MDR. 
The effect of various process parameters (surfactant concentration, power and duration of 
sonication) on the feasibility of stable nanoparticle were studied. The stable formulations used 
in this study exhibited different surface properties. The particles ranging 100-300 nm in size and 
surface properties were reflective of the different types of ‘surface active agent’ and their 
concentration (Table 1). Except CTAB-based cationic NPs, all formulations showed negative 
surface charge and narrow polydispersity index. Amongst all the nanocarriers prepared, CTAB 
NPs showed comparatively higher toxicity in both cell lines. Once the cytocompatibilities of NPs 
were established, all subsequent in vitro studies were performed at a considerably lower 
concentration of 50µg/mL equivalent polymer concentration (approximately 5µL/mL NP 
suspension).  
Nile-red cell adhesion studies were performed in order to understand the dynamics of NP 
adhesion to the cell surface. Detergents and excipients tend to disrupt the P-gp-lipid interface 
affecting functional conformation of efflux transporters. Cell-NP interaction showed 
significantly higher accumulation of nile-red in both cell lines treated with Cremophor® EL, 
PVA+SDS and CTAB NPs post 24hr treatment as compared to an equivalent concentration of 
nile red solution. The results imply an enhanced cell-NP interaction function following NP 
treatment.  
Accumulation studies with both P-gp substrates- calcein AM and rhodamine-123, revealed an 
increasing pattern after approximately 4hour post treatment in the following order- CTAB NP> 
Cremophor® EL NP> PVA+SDS NP. PVA and Tween® 80 NPs were found to be moderately 
effective in overcoming P-gp mediated resistance. Solutol® HS15 NPs showed anomalous 
behavior and resulted in a decreased uptake of calcein compared to that of control group. 
Using rhodamine-123 as P-gp substrate, Solutol® HS15 NP treatment group did not show any 
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significant improvement of P-gp modulatory function. Free Solutol® HS15 units released from 
NP could have trapped hydrophobic rhodamine-123 in micelles which may ultimately get 
blocked in the rigid membranes of drug resistant cell, thereby reducing the substrate uptake. 
This has been observed in previous studies and is responsible for a lower treatment efficacy9,13. 
9L cells have been demonstrated to possess a set of extremely chemoresistant cancer stem-like 
cells (CSLCs)18. High density of P-gp efflux transporters (Figure 1) on cell membrane of 9L cells 
could be responsible for their higher resistance against doxorubicin (Table 2). It has been 
reported that doxorubicin failed to eradicate cancer stem cell populations from anaplastic 
thyroid carcinoma cells19. 
Solutol® HS15 based NPs failed to show therapeutic effects in all assays. Except Solutol® HS15 
NPs, all other formulations showed enhanced uptake of doxorubicin by F98 cells with a lower 
IC50 values of up to 4.8- fold for Cremophor® EL and 2.5-fold for CTAB NPs. 9L cells showed 
around 3-fold reduced IC50 values with these two set of NPs, as compared to doxorubicin-
treated cells (control). 
NPs led to a decrease in cytotoxicity towards doxorubicin compared to free excipients in 
general, which might be due to the fact that during NP preparation, unbound excipients 
molecules may have been washed. Another explanation might be that above critical micellar 
concentrations (CMC), certain excipients as Solutol® HS15 (CMC= 0.02% w/v) and Tween® 80 
(CMC= 0.0016% w/v), can form micelles in free form which can lead to reversal of drug 
resistance due to their interaction with cell membrane.  
Thus, in the context of nanoparticle formulations prepared using different surfactants, 
Cremophor® EL and CTAB based NPs, and to some extent PVA+SDS NPs appear to reverse MDR 
in this study. Cremophor® EL has demonstrated its superiority amongst other excipients on the 
absorption of P-gp substrates in vitro and in vivo in previous studies8,20. CTAB particles on the 
other hand, are known to bind to the negative regions of the cell membrane followed by their 
rapid internalization21 in studies that have previously shown their MDR modulatory ability in 
cancer22,23. 
Recently, liposomes inserted with non-ionic surfactants such as Solutol® HS 15, Pluronic® F68 
and Cremophor® EL were evaluated in P-gp expressing A549/T cells for reversing MDR13. 
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Amongst the three formulations, reduced P-gp expression levels and ATP depletion were 
reported with Solutol® HS15 incorporated liposomes in comparison to Cremophor® EL 
liposomes. In this study, the initial concentration of surfactants used for liposome preparation 
was the same and Solutol® H15 scored better than Cremophor® EL in MDR reversal. However, 
this contradictory outcome in our work could be explained on the basis of different 
concentration of surfactants that were used: Solutol® HS15-0.1% w/v and Cremophor® EL-0.2% 
w/v; and also on the basis of different formulation types in both studies. 
With respect to structural attributes, all non-ionic surfactants used in this study have 
polyethylene glycol (PEG) chains. In comparison to Solutol® HS 15 (PEG15) and Tween® 80 
(PEG20), Cremophor® EL (PEG35) has longer chain. Hydrophilic chains interact with the polar 
head groups of the plasma membrane while the lipophilic head group of surfactant interacts 
with the lipid bilayer6. The long PEG chain in case of Cremophor® EL, causes stronger steric-
repulsion from the polar head groups of plasma membrane making the excipient less toxic than 
the other two surfactants24. Although this does not explain the interaction of excipient with the 
P-gp transporter, the mode of action of free excipient versus nanocarriers developed with same 
excipient may understandably differ. An in-depth and comparative study of interaction pattern 
between excipient-lipid bilayer and excipient-based NP-lipid bilayer can provide a better 
understanding of the P-gp inhibition step. As the particles are localized within the tumor mass, 
the risk of excipient exposure elsewhere in the body can be presumed to be minimal. Further 
elaborate in vivo studies can help to understand the pharmacokinetics of excipient-based NPs. 
Once, these interactions are chalked out, it would be interesting to manoeuvre different 
‘surface active‘ MDR modulators and utilize them in preparing chemosensitizing drug delivery 
systems. 
The concentrations at which these excipients mediate P-gp modulation are much lower than 
used in clinical applications for drug delivery. Hence, surfactant-based formulations can offer 
promising alternatives compared to regular nanocarriers with their ability to 1) deliver anti-
cancer payload to the tumor tissue, 2) sensitize drug resistant cells towards anti-cancer drugs, 
3) improve unfavourable pharmacokinetic side effects associated with drug-clearance, and 4) 
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deliver an MDR inhibitor which can not only act as a ‘dual strategy’ for reversing MDR, but also 
reduce the systemic toxicity due to high doses of commercial inhibitors. 
 
3.6. Conclusion 
Amogst the ionic and non-ionic surfactants tested, Cremophor® EL NP and CTAB NP showed 
most efficient MDR reversal activities when co-administered with doxorubicin in highly resistant 
glioma cell lines. Moderate effects were also observed with anionic- SDS NPs in the less 
resistant cell line. More than just carrying anti-cancer drug payload and P-gp inhibitors, these 
nanocarrier systems can circumvent MDR by evading drug efflux transporters. Further studies 
aimed at understanding NP-cell interactions would facilitate the development of these specific 
‘surface active’ nanoformulations. Such ‘surface active’ drug delivery systems appear promising 
and can well be considered as the fourth generation of MDR inhibitors for the treatment of 
clinical MDR in cancer. 
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4. Chapter 2: 
Cargoing P-gp inhibitors via nanoparticle sensitizes tumor 
cells against doxorubicin 
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4.1. Abstract 
Inhibitors against multidrug resistance (MDR) efflux transporters have failed in most clinical 
settings due to unfavorable pharmacokinetic interactions with co-administered anti-cancer 
drug and their inherent toxicities. Nanoparticles (NPs) have shown potential to overcome drug 
efflux by delivering and localizing therapeutic molecules within tumor mass. In this work, we 
investigated effect of nanocarrier surface charge and formulation parameters for a hydrophilic 
and lipophilic MDR inhibitor on their ability to reverse drug resistance. Active inhibition of efflux 
pumps was achieved by encapsulating first and third generation P-gp inhibitors- verapamil and 
elacridar respectively in non-ionic, anionic and cationic surfactant-based NPs. The ability of NPs 
to reverse P-glycoprotein (P-gp)-mediated MDR efflux was evaluated in sensitive (A2780) and 
resistant (A2780Adr) ovarian cancer cell lines by various in vitro accumulation and cytotoxicity 
assays. Uptake mechanism for NP appears to be caveolae-dependent with 20%-higher 
internalization in A2780Adr than A2780 cell lines which can be co-related to the biophysical 
membrane composition. Cationic- CTAB NPs showed highest reversal efficacy followed by PVA 
and SDS-NP (P+S-NP) and PVA-NPs. As compared to doxorubicin treated drug resistant cells 
lines, blank-, verapamil- and elacridar-CTAB-NPs showed 2.6-, 20- and 193-fold lower IC50 
values. This work highlights the importance of inhibitor-loaded charged particles to overcome 
cancer drug resistance. 
  
  4. Chapter 2 
 
59 
 
4.2. Introduction 
Members of the ATP-binding cassette (ABC) superfamily of transmembrane transporters such 
as P-gp, multidrug resistance protein (MRP) and breast cancer resistance protein (BCRP) are 
expressed at various physiological barriers (gastrointestinal tract, lung, kidney, blood-brain 
barrier) and play protective roles against xenobiotics and in drug metabolism and excretion 
from the body. An over-expression of one or more of these transporters in tumor cells leads to 
recognition and systematic efflux of anti-cancer drugs and their structural analogues, clinically 
referred to as the multidrug resistance (MDR) in cancer. 
MDR is the cause of failure of most chemotherapeutic regimens in cancer treatment and also 
for cancer relapse. Treatment regimens employing proper P-gp inhibitor and P-gp substrate 
combination can check development of cancer drug resistance by potentiating synergistic 
actions. Different generations of pharmacological MDR inhibitors have been researched in last 
decades but most drug trials were disappointing as the inhibitors lack specificity and exhibit 
high systemic toxicity amongst other reasons1. Other factors such as the limited solubility of P-
gp inhibitors in aqueous solution and low availability at the tumor site have also contributed to 
the failure of P-gp inhibitors in overcoming MDR in cancer. 
Drug delivery systems offer promising alternative for transportation of an array of molecules 
enabling anti-cancer drug uptake in cancer cells2. In most of the studies done so far, a 
combination of anti-cancer drug and/ or P-gp inhibitor were co-administered in a multitude of 
carriers (lipid nanocapsules3, liposomes4, microspheres5) to sensitize drug resistant cells to 
chemotherapy. As there are already many market approved nano-based anticancer drugs such 
as Doxil® or Abraxane®, focus should be diverted towards the safe and localized delivery of 
MDR-inhibitors to the tumor mass. This is of urgent attention due to the fact that the ABC 
transporters are constitutively expressed in different barrier tissues and administration of MDR 
inhibitors as a formulation reduces the risk of systemic exposure and interference in routine 
functioning of these transporter proteins. Moreover, an optimal concentration of MDR 
inhibitors can be attained locally at the tumor site due to enhanced permeability and retention 
(EPR) effect.  
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To this effect, only Binkhathlan and colleagues have done an extensive in vivo investigation 
using valspodar-loaded methoxy-poly(ethylene oxide)-block-poly(e-caprolactone) (PEO-b-PCL) 
micelles6. Use of micellar drug delivery systems, not only improved valspodar solubility but 
reduced its pharmacokinetic interactions with co-administered doxorubicin solution in Sprague-
Dawley rats. Thus, nanocarriers are efficient in reducing the effective dose of P-gp modulator at 
which they attenuate P-gp-mediated efflux activity and improve their bioavailability at the 
pharmacological site of action. 
Drug resistant cells have highly rigid and compact cellular membrane due to altered 
phospholipid profiles7. As nanoparticle surface is the first to interact with lipid bilayer, it is 
important to characterize charge-dependent sensitization of drug resistant cells. In our previous 
work, nanoparticles with different ‘surface active agents’ were evaluated for their ability to 
overcome MDR [Chapter 2]. In order to obtain complete reversal and evaluate the effect of 
particle charge, inhibitor-loaded NPs were developed with non-ionic (polyvinyl alcohol (PVA)), 
cationic (cetyltrimethylammonium bromide (CTAB) and anionic (sodium dodecyl sulphate (SDS) 
surfactants. P-gp inhibitors- verapamil hydrochloride (VRP) and elacridar were chosen due to 
their different solubility profiles, were loaded in aforementioned NPs and tested in present 
work. To compare the quantitative efficacy, we used P-gp expressing, adriamycin resistant 
human ovarian cancer cell line A2780Adr and its parental cell line A2780 as control. 
4.3. Materials and Methods 
4.3.1. Materials 
Poly-lactide-co-glycolide (PLGA) RG 502 H was obtained from Boehringer Ingelheim (Ingelheim, 
Germany). Polyvinyl alcohol (PVA, Mowiol® 4-88) and verapamil hydrochloride were kind gift 
from Kuraray (Frankfurt, Germany) and Fagron (Barsbüttel, Germany) respectively. Sodium 
dodecyl sulphate (SDS) and cetyltrimethylammonium bromide (CTAB) were obtained from Carl 
Roth (Karlsruhe, Germany) and Fluka Analytical respectively. Elacridar (CAS: 143664-11-3) was 
synthesized in-house with a purity of > 98%. Rhodamine-123, calcein AM, doxorubicin, 3-(4,5-
Dimethyl-2-thiazolyl)-2,5-diphenyl-2-tetrazolium bromide (MTT), nile red, wheat germ 
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agglutinin-FITC, DAPI and all other solvents and reagents were obtained from Sigma Aldrich 
(Steinheim, Germany) and were of analytical grade. 
4.3.2. Cell lines 
The human ovarian carcinoma cell line A2780 and the corresponding P-gp over-expressing 
adriamycin resistant A2780Adr cell line (ECACC Nos. 93112519 and 93112520)were kind gift 
from Prof. Dr. Michael Wiese, Department of Pharmaceutical Chemistry II, University of Bonn. 
The cell lines were grown in RPMI-1640 medium supplemented with 10% FBS, 50µL/mL 
streptomycin, 50 U/mL penicillin G, and 2 mM L-glutamine. All cell lines were cultivated in a 37 
°C incubator with 5% CO2/ 95% humidified air. Subculturing was performed after confluence of 
80-90%, using 0.05% trypsin and 0.02% EDTA. All cell culture grade chemicals were purchased 
from Sigma Aldrich. 
4.3.3. Preparation and characterization of nanoparticles 
Internal phase was prepared by dissolving 20 mg PLGA in 400 µl dichloromethane. This was 
poured in 2 mL of aqueous phase (1% PVA/ 1% PVA and 0.05% SDS/ 0.02% CTAB solution) and 
ultrasonicated (50% duty cycle for 30sec). The organic phase of internal phase was evaporated 
by stirring for 3hr. 4 mg VRP or 0.4 mg elacridar were added to internal phase to prepare 
verapamil (VNP) or elacridar NPs (ENP). Blank nanoparticles were prepared analogously without 
the addition of either inhibitor. With three surfactants (PVA/ SDS/ CTAB) and two generations 
of P-gp inhibitors- VRP and elacridar, nine different formulations were prepared (Table 1). Nile 
red NPs were similarly prepared by adding 40µl of 0.1% nile red solution in the organic phase 
and contained no inhibitors. Nanoparticles were analyzed for their size distribution, 
polydispersity index (PDI) and zeta potential using a ZetaPlus (Brookhaven Instruments 
Corporation). Each sample was analyzed in triplicate.  
4.3.4. Encapsulation efficiency and inhibitor release 
The encapsulation rate was analyzed indirectly by determining the amount of non-encapsulated 
drug in the external aqueous phase by high-performance liquid chromatography (HPLC). For 
determining the encapsulation efficiency of VRP following parameters were used: mobile 
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phase- KH2PO4 buffer (pH 3.0 adjusted with orthophosphoric acid): acetonitrile (60:40), flow 
rate 1.0 mL/min, wavelength 278 nm, LiChrospher® 60 RP-Select-B column (Merck, Germany) 
using a Waters 2695 with Photodiode Array Detector Waters 996 (Eschborn Germany).The 
amount of elacridar encapsulated within the NPs was detected using methanol: water (85:15), 
flow rate 1.5 mL/min, wavelength 254, Eurospher II 100-5 C18H (50 x 4 mm) column connected 
with a pre-column Vertex-Plus Eurospher II 100-5 C18H (5 x 4 mm) (Knauer, Germany). Samples 
were prepared in triplicate and encapsulation yield (%) was determined by dividing the 
experimental drug payload by the theoretical payload. 
In order to assess the drug release, 2 mL of each NP preparation was taken in triplicate and kept 
at 37° C in a shaking water bath. Phosphate buffered saline (pH 7.4) was chosen as release 
buffer with 0.1 % Tween® 80 to maintain sink conditions. At predefined time points 0.5 mL of 
release medium was withdrawn and replaced by 0.5 mL of fresh buffer for continuous release. The 
amount of drug in the release medium was quantified for the respective MDR inhibitor by HPLC as 
mentioned before. 
4.3.5. Confocal Laser Scanning Microscopy 
Cells were grown over coverslips in 24 well plate and incubated with nile red nanoparticles for 
4hr. Free nile red was removed by several washing steps followed by incubation with wheat 
germ agglutinin-FITC at 4°C for 30min. Fixation was performed with paraformaldehyde (4%) 
followed by nuclear staining with DAPI (300nM; 5min). Slides were prepared with glycerol/PBS 
and imaged with a Biorad Laser Scanning Confocal Imaging System. 
4.3.6. Calcein AM accumulation assay 
For determining the effect of encapsulated inhibitors on P-gp,a calcein AM accumulation assay 
was performed as described earlier (Chapter 2).Following trypsization and centrifugation of 
A2780 and A2780Adr cells and repeated washing steps with Krebs-Hepes buffer (KHB) cells 
were seeded into black 96 well plates (Greiner, Frickenhausen, Germany) at a density of 
approximately 20,000 cells per well to which 2.5 and 0.25 µg/mL of inhibitors VRP and elacridar 
and their NP equivalent were added. After a 30 min pre-incubation period, 2.5 µM calcein AM 
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solution was added to each well. The fluorescence was measured immediately in constant time 
intervals (60s) up to 240 min at an excitation wavelength of 485 nm and an emission 
wavelength of 520 nm with a BMG POLARstarmicroplate reader maintained at 37°C. 
4.3.7. Rhodamine-123 uptake assay 
To re-evaluate the effect of inhibitors on P-gp, a rhodamine-123 accumulation assay was 
performed as it is a known P-gp substrate. 10,000 cells each of A2780Adr and A2780 were 
seeded in 96 well plates and incubated overnight for adherence. Rhodamine-123 (0.3 µM) 
together with inhibitor (similar concentrations as in calcein AM assay) and equivalent NP 
treatment were administered in serum-free media. Following incubation for 6 hrs, media was 
removed, and wells washed once with PBS. 100µl Triton-X 100 (1% v/v) was added to each well 
and incubated for 30 min to lyse cells and extract rhodamine-123. The fluorescence was 
measured (ex = 505 nm, em = 540 nm) with a fluorescence spectrophotometer (Victor3, Perkin 
Elmer) and normalized for cellular protein levels as determined by bicinchoninic acid (BCA) 
assay. 
4.3.8. In vitro cytotoxicity assay 
In order to determine the toxicity of different formulations, cells were incubated with different 
blank (PVA, P+S and CTAB) nanoparticle preparations of equivalent polymer concentrations 
(500- 0.1µg/mL) for 24 hr. The sensitive counterparts of these cells were used as controls. 
Approximately 5,000 cells per well were seeded in 96 well plates and grown in DMEM 
overnight. Control experiments were performed with medium containing 10% (v/v) DMSO.  
After an incubation period of 72hr MTT was added (5mg/mL) and further incubated for 1hr. 
Formazan crystals formed were solubilized by adding 100 µl DMSO per well and measured 
photometrically at 544 nm using a plate reader (Victor3, Perkin Elmer). The cell viability was 
calculated using an untreated control as reference. To check the effectiveness of encapsulated 
inhibitors to reverse the drug resistance in P-gp (A2780Adr) over-expressing cells to doxorubicin 
MTT cytotoxicity assays were performed. Cells were treated with doxorubicin at different 
concentrations in a volume of 10µL. 2.5 and 0.25µg/mL of inhibitors VRP and elacridar and their 
NP equivalent were added to each well to achieve the final volume of 100µl. 
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4.3.9.  Mechanism of nanoparticle endocytosis 
Approximately 25,000 cells were seeded in 96-well plates and grown overnight for adherence. 
Cells were pre-incubated for 30 min with different endocytosis inhibitors at following 
concentrations: chlorpromazine hydrochloride- 10µg/mL8, nystatin- 0.069mg/mL9, methyl-β-
cyclodextrin (MβCD)- 10mmol/L10, 5-(N,N-dimethyl)amiloride hydrochloride (DMA)- 
0.44mg/mL9, Cytochalasin D- 10µg/mL8 (all from Sigma) in HBSS serum-free media. 
Subsequently, nile red NPs were added and incubation further continued for 2 hr. After washing 
with PBS, 100µL isopropanol was added and the absorbance of nile red measured at (544nm/ 
615nm) with a plate reader (Victor 3, Perkin Elmer). Energy dependence experiments were 
performed similarly by pre-incubating the cells at 4°C for 30 min prior to exposure to NPs. Nile 
red NP treated cells without inhibitors was used as control.  
4.3.10. Statistical Analysis 
All the experiments were performed in triplicates and reported as mean ± S.D. Statistical 
comparisons were made with one-way ANOVA followed by Dunnett’s post test using GraphPad 
Prism software version 5.0. In all cases, p< 0.05 was considered to be significant at 95% 
confidence level. 
4.4. Results 
4.4.1. Physicochemical characterization 
Physicochemical properties of blank and inhibitor (VRP and elacridar) loaded formulations are 
shown in Table 1. PVA and P+S NPs were comparatively larger in size than CTAB NPs within 
each subgroup. Inhibitor loading led to an increase in size of all NP’s compared to blank 
particles. All formulations exhibited narrow size range as evident from polydispersity index 
(PDI). Zeta potential was strongly affected by the surfactant used and exhibited strongest 
negative and positive surface charge with anionic (SDS) and cationic (CTAB) surfactant 
respectively. 
Two sets of cytotoxicity assays were performed. To assess toxicity exhibited by different NPs 
against both resistant and sensitive cell lines, MTT assays were done for 24hr with varying NP 
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concentrations. Except CTAB NPs, none of the formulations were cytotoxic up to 500µg/mL NP 
concentration (A2780Adr: LC50-275.4±70.5µg/mL, A2780: LC50-209±15µg/mL). In all subsequent 
in vitro assays an NP concentration of less than 10µg/mL was used. MTT results with 
doxorubicin are mentioned in section 3.6. 
 
 Size 
(nm) 
PDI Zeta potential 
(mV) 
   Encapsulation (%) 
Verapamil/ Elacridar 
Blank-PVA NP   (B-PVA) 230.1 
(± 1.8) 
0.167 
(± 0.08) 
-12.59 
(± 1.8) 
- 
Blank-PVA+SDS NP   (B-P+S) 247.7 
(± 9.9) 
0.128 
(± 0.01) 
-18.29 
(± 2.33) 
- 
Blank-CTAB NP   (B-CTAB) 187.4 
(± 14.2) 
0.178 
(± 0.05) 
5.49 
(± 1.58) 
-  
Verapamil-PVA NP   (V-PVA) 292.9 
(± 3.7) 
0.106 
(± 0.03) 
-12.96 
(± 0.83) 
26.7 (± 1.4) 
Verapamil- PVA+SDS NP   (V-P+S) 312.2 
(± 5.4) 
0.066 
(± 0.03) 
-18.45 
(± 0.84) 
47.9 (± 0.2) 
Verapamil-CTAB NP   (V-CTAB) 195.4 
(± 1.1) 
0.169 
(± 0.03) 
6.52 
(± 0.95) 
11.8 (± 0.6) 
Elacridar- PVA NP   (E-PVA) 356.5 
(± 9.2) 
0.051 
(± 0.08) 
-14.57 
(± 1.62) 
89.3 (± 8.3) 
Elacridar- PVA+SDS NP   (E-P+S) 369.4 
(± 9.4) 
0.087 
(± 0.03) 
-18.67 
(± 1.78) 
95.8 (± 5.2) 
Elacridar-CTAB NP   (E-CTAB ) 223.3 
(± 45.2) 
0.16 
(± 0.01) 
5.79 
(± 0.85) 
84.3 (± 8.8) 
 
Table 1. Physicochemical characterization of NP formulations encapsulating verapamil/ elacridar; or 
without inhibitor (blank NPs). Size, polydispersity index (PDI) and zeta potential was measured by PCS. 
Encapsulation efficiency was calculated based on the theoretical content of inhibitors. (Mean± SD; n=3). 
 
4.4.2. Encapsulation efficiency and release 
Encapsulation efficiency showed marked difference in encapsulation of the two inhibitors 
(Table 1). Elacridar being highly lipophilic was encapsulated around 90% in all formulations 
irrespective of the surfactant used. Verapamil, due to its cationic character showed varying 
encapsulation rates depending on the surfactant used and the subsequent ionic interactions 
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with them. Encapsulation was highest in anionic- P+S NPs (47.9 ± 0.2%) and lowest in cationic-
CTAB NPs (11.8 ± 0.6%). Cumulative release of both inhibitors showed biphasic pattern of fast 
initial release within the first 12hr followed by a further slow and continuous release; a 
characteristic of PLGA-based NPs (Figure 1).  
 
 
Figure 1. Cumulative release of verapamil- and elacridar-loaded nanoparticle formulations in PBS at 
physiological pH (7.4) plotted against time. (Mean ± SD; n = 3) 
 
4.4.3. Confocal Microscopy 
Confocal images of A2780 resistant were taken following treatment with PVA, P+S and CTAB 
nile red NPs (Figure 2). Interaction between all NPs and cells was higher in sensitive cells than 
the resistant ones as expected. Microscopic images showed strong presence of CTAB NPs 
exhibiting a strong interaction between NP and cell membrane after 4hr NP treatment which 
was followed by P+S NPs followed by PVA NPs to some extent. 
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Figure 2. Confocal images of A2780Adr cell lines. The cells were incubated for 4hr with three different 
nile red NP formulations (red channel). a. control untreated; b. PVA NP; c. P+S NP; d. CTAB NP. The cell 
membrane was stained with wheat germ agglutinin (green) and the nucleus with DAPI (blue). Scale bar 
represents 5µm.  
4.4.4. Calcein AM accumulation assay 
The ability of inhibitor and their corresponding NP’s to modulate P-gp function was evaluated 
using the calcein AM assay in P-gp over-expressing A2780Adr cells. The results depicted in 
Figure 3 represent rate of accumulation of calcein (a fluorescent P-gp substrate) within cells in 
4.5hr span. Except blank particles of PVA and P+S, all treatment groups led to significant rate of 
accumulation as compared to untreated, calcein AM administered resistant cells (A2780Adr), 
which could be attributed to inhibitor-induced chemosensitization (except blank NPs). Owing to 
the higher adherence of CTAB NPs to cell membrane, all cationic formulations (blank, verapamil 
and elacridar) showed marked increase in calcein accumulation. As V-CTAB NPs exhibited low 
encapsulation and higher release rate, in order to avoid enhanced cell-adhering and uptake 
effects of CTAB NPs, V-CTAB NPs were used at one-fourth equivalent of VRP concentration 
(2.5µl/mL NP by volume) in all subsequent in vitro experiments. Although used at 10-fold lower 
concentration than VRP, elacridar and its respective formulations gave higher rates of calcein 
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accumulation demonstrating higher potency of the third-generation inhibitor. A combination of 
elacridar and CTAB NPs led to near complete sensitization of drug resistant cells at par with 
parental cell line (A2780). 
 
Figure 3. Calcein AM accumulation following treatment with different formulations for 4hr in KHB 
buffer. *p < 0.05 compared to untreated adriamycin resistant A2780 cells, One-way ANOVA followed by 
Dunnett’s post test. (Mean± SD; n=3) 
4.4.5. Rhodamine-123 uptake assay 
Rhodamine-123, another P-gp substrate and fluorescent dye was used to study the effect of P-
gp inhibition and the results were similar to those obtained with calcein. Rhodamine-123 
uptake enhanced in all treatment groups as compared to the drug resistant cell lines (Figure 4).  
Accumulation was significantly high in both inhibitor-loaded CTAB NPs but not as significant in 
inhibitor solution, PVA NP and P+S NP treated cells. Elacridar-loaded CTAB NPs showed 
rhodamine-123 accumulation in resistant cells equal to A2780 sensitive cell lines demonstrating 
complete MDR reversal within 6hr of treatment. 
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Figure 4. Rhodamine-123 accumulation assay following treatment with different formulations for 6hr in 
serum-free media; (Mean ± SD; n=9). ; *p < 0.05 compared to untreated adriamycin resistant A2780 
cells, One-way ANOVA followed by Dunnett’s post test. 
4.4.6. Cytotoxicity with anti-cancer drugs 
To determine the MDR reversal ability of inhibitors and their nanoparticles, the MTT assay was 
performed using P-gp substrate doxorubicin. Sensitive and resistant cells were incubated for 72 
hr in presence of different concentrations of doxorubicin and a fixed concentration of the 
inhibitors or their NPs. Exposure to inhibitors and their NP formulations resulted in sensitization 
of resistant cells. The reversal efficiencies is defined by the following: 
 
In general, as compared to doxorubicin treated drug resistant cells lines, blank-, verapamil- and 
elacridar-CTAB-NPs showed 3-, 20- and 193-fold lower IC50 values (reversal efficacies). This was 
followed by blank-, verapamil- and elacridar-P+S-NPs exhibiting 2-, 15- and 36- fold lower IC50 
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values. Resistance ratio with respect to the parental cell lines showed highly significant results 
in both VRP and elacridar treatment groups and complete reversal (Figure 5). Unlike treatment 
with inhibitor solution, sustained release of inhibitors from NP core over the period of 
treatment can play crucial role by sensitizing the drug resistant cells towards cytotoxic drug and 
reverting the condition. Amongst blank NPs, CTAB particles exhibited maximum P-gp inhibition 
in line with previous accumulation assays followed by P+S. The ability of blank particles to 
inhibit P-gp transporter could be reasoned out due to their surfactant-cell membrane 
interactions property which has been demonstrated previously (Chapter 2 reference). All 
elacridar-based NPs demonstrated a complete reversal showing highest efficacy when 
incorporated in CTAB NPs. 
 IC50 (nM Doxorubicin) Reversal efficiency 
A2780 5.8 ± 1.5a  
A2780Adr 212.8 ± 44.4f  
B-PVA NP 202.3 ± 34.1 1.2 ± 0.1 
B-P+S NP 139.0 ± 51.4a 1.8 ± 0.3 
B-CTAB NP 94.6 ± 21.5a 2.6 ± 0.0 
VRP-HCl solution 52.8 ± 13.8a 4.6 ± 0.2 
V-PVA NP 47.5 ± 3.2a,d 5.1 ± 0.8d 
V-P+S NP 16.4 ± 3.2a,b,e 14.7 ± 0.4b,e 
V-CTAB NP 13.0 ± 6.1a,b,f 20.5 ± 6.3b,f 
ECR solution 34.9 ± 4.1a 6.9 ± 0.7 
E-PVA NP 6.8 ± 1.0a,c,d 34.5 ± 2.5c,d 
E-P+S NP 6.8 ± 1.1a,c,e 35.6 ± 2.2c,e 
E-CTAB NP 1.2 ± 0.2a,c,f 193.3 ± 6.5c,f 
 
Table 2. IC50 values of NP formulations following MTT assay in cells for 72h. Reversal efficacy was 
calculated from rations between the mean IC50 values of free doxorubicin and that of other various 
formulations in A2780Adr cell lines. Data are shown as Mean ± S.D. (n=3) ap< 0.05 compared with 
doxorubicin treated resistant cell line. bp< 0.05 compared with verapamil hydrochloride solution. c p< 
0.05 compared with elacridar solution. d p< 0.05 compared with B-PVA NP. e p< 0.05 compared with B-
P+S NP. f p< 0.05 compared with B-CTAB NP. 
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Figure 5: Resistance ratio denotes the quotient of IC50 value of the inhibitor/NP treated resistant cell line 
to that of the doxorubicin treated parental cell line. *p< 0.001 two-way ANOVA. 
 
4.4.7. Mechanism of endocytosis in resistant and sensitive cells 
In order to understand the mode of internalization of NPs in drug resistant and drug sensitive 
cell line, well characterized inhibitors of known endocytic pathways were used. Nanoparticles 
did not show much difference on the basis of surface charge in drug resistant cells (Figure 6). 
Clathrin-dependent uptake can be ruled out as no significant differences were observed with 
chloropromazine treatment. MβCD showed 70-80% inhibition of nile-red particles uptake in 
A2780Adr cells implying a caveolae-dependent uptake. Interestingly, in drug sensitive 
counterpart A2780 cells, MβCD inhibited endocytosis by only 50-60% compared to control. This 
corroborates with previous reports, where NP sized more than 200nm were shown to be 
uptaken via caveolae-dependent mechanism11,12. Nystatin, which seqesters cholesterol, 
however did not affect the uptake process in either cell lines. Dimethyl amiloride and 
Cytochalasin D, both of which affect macropinocytosis process did not appear to influence 
internalization of NP and this was expected as macropinocytosis is usually done by professional 
antigen presenting cells of the immune system. In drug resistant cells- approximately 40% and 
in drug sensitive cells- 50% uptake seems to be due to passive diffusion (4°C treatment). This 
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might be due to the size distribution of particles which in turn affects dose limitations to the 
target cells. Another notorious factor can be the adsorbed NP on cell surface which are not 
internalized and are difficult to remove even after repeated washing steps. Heavy 
concentration of CTAB NPs was also observed by confocal microscopy following 2hr incubation 
with nile red NPs (Figure2d). Higher accumulations of adsorbed NP on membrane surface has 
also been reported by Vranic et al9 as well which affect the accurate analysis of internalization 
pathway. CTAB NPs (187.4± 14nm) which are on the borderline of 200nm size (< 200nm is the 
upper limit for clathrin-dependent endocytosis) can well be uptaken by clathrin coated vesicles 
(chlorpromazine treatment) but their internalization mechanism appears to differ in the two 
cell lines. In resistant cells, due to densely packed membrane, and intrinsic efflux property, NP 
internalization might be difficult. On the contrary, in sensitive cell line, a significant 23% uptake 
seems to be accomplished via clathrin-coated vesicles together with caveolae-dependent 
endocytosis (approx. 45%).  
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Figure 6: Nile red uptake (%) following incubation of A) A2780 and B) A2780Adr cell lines with inhibitors 
of endocytosis pathway and nile red NP. Active uptake was blocked by incubation at 4°C. Control group 
were incubated with nile red without inhibitor treatment. 
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4.5. Discussion 
Purpose of this work was to investigate the ability of P-gp inhibitor-loaded surfactant-based 
nanoparticles to sensitize drug resistant cells towards co-administered P-gp substrates. First 
and third generation inhibitors-verapamil hydrochloride and elacridar respectively were 
encapsulated in non-ionic, anionic and cationic NPs. Third generation inhibitor- elacridar is 
more potent and the hydrophobicity can yield high entrapment efficiency. In contrast, 
entrapment of hydrophilic- verapamil poses challenge due to the hydrophobic nature of PLGA13 
and leaching out into aqueous phase. This reflected in both encapsulation efficiencies (Table 1) 
and release profile (Figure 1) of verapamil loaded NPs.  
PVA-SDS NPs exhibited comparatively higher entrapment but low release of VRP in contrast to 
V-CTAB NPs which could be explained due to the electrostatic interactions between drug 
molecules and surfactant. On the other hand, elacridar showed a high rate of encapsulation in 
all formulations due to their highly lipophilic character. Over 50% incorporated drug was 
released from all formulations in first 6 hr, except V-P+S NPs (41.6 ± 5.7%) wherein a strong 
ionic interactions between cationic drug and anionic surfactant (SDS) could be responsible for a 
slower release. In contrast, rate of release of VRP was highest in CTAB particles due to repulsion 
between cationic surfactant CTAB and drug molecules. 
In order to visualize differential NP-cell membrane interactions, nile red-loaded, surfactant-
based NPs were prepared and used to treat drug resistant cells. The interaction between NPs 
and cells was charge-dependent. Highest adherence was observed with cationic- CTAB particles 
which could be due to the negatively charged cell membrane. This was followed by anionic-
PVA+SDS particles and to a lesser extent PVA NPs. To assess quantitative advantage of all 
formulations various in vitro assays were performed with P-gp substrates. 
Elacridar (0.25 µg/mL) was used at 10-fold lower concentration than the first generation 
inhibitor verapamil (2.5 µg/mL) in all assays. Equivalent concentrations of respective NPs were 
used for treatment in all in vitro assays except V-CTAB as aforementioned in section 3.4. Both 
calcein and rhodamine-123 are P-gp substrates and an increased accumulation marks P-gp 
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inhibition in resistant cell lines. A correlation with the inhibitor-release profile suggests almost 
50% release from almost all inhibitor-loaded formulations at 6hrs; at which time frame, it was 
obvious that a complete sensitization is difficult to achieve as mentioned in previous work14. 
Treatment with different formulations in both assays yielded similar result profiles with CTAB-
based NPs showing highest drug reversal. However, both PVA- and PVA+SDS-NPs did not show 
significant difference over each other although inhibitor-loaded NPs were significantly better in 
sensitizing drug resistant cells compared to untreated group.   
In vitro cytotoxicity results with doxorubicin (72hr treatment with NP) presented an 
extrapolation of in vitro accumulations assays with a clear order of efficacy as follows: CTAB NP 
> PVA+SDS NP > PVA NP. This was possible due to an extended period of release of inhibitors 
from NP and sensitization of drug resistant cells to complete reversal. 
Overall the results appear to show charge and surfactant-dependence on P-gp modulatory 
properties of particles. Several reasons might be responsible to support our findings of higher 
efficacy with cationic NPs in overcoming drug resistance which have also been demonstrated 
recently with other cationic surfactants as well15,16. Drug resistant cells have altered membrane 
properties, such as presence of higher amounts of cholesterol and sphingomyelin17. Negatively 
charged cholesterol in drug resistant cells might be responsible for an enhanced adhesion of 
CTAB NPs to the cell membrane. Experiments to support this were, however, out of the scope 
of present study. 
Uptake of particles in both drug resistant and sensitive cells was largely clathrin-independent 
implying involvement of either or both cholesterol-rich membrane microdomains namely 
caveolae and lipid rafts18. Methyl-β-cyclodextrin is known to knock out cholesterol out of lipid 
rafts, rendering the membrane more fluid19 which in turn perturbs formation of clathrin-coated 
vesicles due to non-availability of cholesterol20. As observed in our results, with MβCD 
treatment (Figure 6), cholesterol-rich drug resistant cells showed almost 20% more uptake by 
caveolae-dependent pathway than their sensitive counterparts. However, the difference in 
uptake mechanisms on the basis of particle surface charge was not very prominent, which may 
be due to the similar size range of particles used (~170-240nm). 
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In a recent work, didodecyldimethylammonium bomide (DMAB) and CTAB were shown to 
exhibit higher biophysical interaction with the lipid extracts (measured in terms of change in 
surface pressure of membrane) of resistant cell than with those of non-transporter expressing 
endothelial cells which co-related with the higher uptake in the former16. Of the two 
surfactants, DMAB with two chains showed higher efficacy than single chained-CTAB. Cationic 
particles are known to induce fluidity in the lipid bilayer as well21 which in turn has been 
accounted for P-gp inhibition and substrate uptake by mild detergents such as Tween® 20 or 
TritonTM X-10022. 
On the other hand anionic particles bind lesser and rather non-specifically to the few cationic 
sites present on plasma membrane causing local gelation21. In this work, PVA+SDS-based NPs 
showed relatively higher P-gp inhibition than PVA NPs. Anionic detergent SDS have been shown 
to enhance intracellular accumulation of epirubicin in Caco-2 cells23 in previous studies 
although a specific mechanism is yet to be ascribed for the enhanced P-gp modulatory activity.  
Comparable to the ongoing efforts towards achieving localized therapeutic effect of anti-cancer 
drug; it is of imminent importance to deliver P-gp inhibitor/s at tumor-site, due to expression of 
the drug resistant transporters at physiologically relevant tissues2. Exposure of inhibitors to 
non-target, non-tumor sites can lead to unfavorable pharmacokinetics of toxic compounds and 
have been the cause for failure of clinical trials even with inclusion of third generation 
inhibitors24. Drug delivery systems can offer 1) localized cancer therapeutics, 2) prevent 
undesirable pharmacokinetic interactions between P-gp modulator and P-gp substrate, and 3) 
sustained release of inhibitors which would ensure prolonged sensitization of drug resistant 
tumors towards cytotoxic drug. 
As the surface of nanoparticle first to interact with cell membrane, it would be ideal to use P-gp 
modulatory surfactants in formulations incorporating commercial inhibitors to achieve two-
stepped inhibition for complete sensitization and reversal of drug resistance.  Delivery of anti-
cancer drug in nanocarriers with intrinsic P-gp modulatory constituents is showing promising 
results2,3. Moreover, efforts are underway to characterize routinely used excipients which as 
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component of nanoformulation would be able to inhibit MDR transporters thereby overcoming 
MDR in cancer. 
4.6. Conclusion 
In this study, the effect of P-gp inhibitor-loaded, non-ionic, anionic and cationic surfactant-
based nanoparticles were evaluated for their ability to sensitize drug resistant cells towards 
doxorubicin. Third-generation inhibitor- elacridar exhibited high encapsulation efficiency, 
sustained release profiles and high potency in drug accumulation and cytotoxicity assays in 
comparison to the first generation inhibitor-Verapamil hydrochloride based nanoparticles. 
Overall, cationic nanoparticles- blank or inhibitor-loaded resulted in higher sensitization of drug 
resistant cells towards P-gp substrates. Efficacy of both- verapamil and elacridar were enhanced 
when delivered via nanoparticles in longer duration treatments due to the sustained release of 
inhibitors and a consequent prolonged sensitization of resistant cells. As observed from this 
study, charge of the surfactants and their inherent membrane binding and P-gp modulatory 
activity can be utilized to achieve higher sensitization than achieved by delivery of inhibitor 
alone to improve therapeutic outcome in treating drug resistant tumors. 
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5. Chapter 3: 
Evaluation of dual P-gp-BCRP inhibitors as nanoparticle 
formulation 
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5.1. Abstract 
Overcoming multidrug resistance (MDR) in cancer is a major challenge and efforts are going on 
to develop inhibitors against the MDR transporters P-glycoprotein (P-gp), multidrug resistance-
associated protein (MRP1) and breast cancer resistance protein (BCRP). Recently, two 4-
anilinoquinazolines KCJ-160 and KCJ-199 demonstrated potential MDR reversal activity against 
BCRP and to a lesser extent, P-glycoprotein. These compounds were formulated as 
nanoparticles (KCJ-160NP and KCJ-199NP) and assessed for their multidrug resistance inhibitory 
activity. Particles in the size range 300-350 nm with a loading efficiency of 69% (KCJ-160NP) and 
77% (KCJ-199NP) respectively were prepared. BCRP inhibition (at 1 µM equivalent) was evident 
as observed in Hoechst 33342 and pheophorbide A assays (in BCRP over-expressing MDCK BCRP 
cells) while P-gp inhibition (at 5µM equivalent) was evaluated by calcein AM and rhodamine-
123 assays (in P-gp over-expressing A2780Adr cells). Cytotoxicity assay with SN-38 in MDCK 
BCRP cells showed complete reversal in nearly all treatment groups (solution and NP). On the 
other hand, cytotoxicity assay with doxorubicin in A2780Adr cells caused complete reversal in 
NP treated group more than observed with free solution. The results demonstrate promising 
inhibitory activity of both selected compounds and their nanoparticle formulations against 
BCRP and P-gp establishing them as dual-inhibitors. It is imperative to investigate both 
inhibitors in animal models of multidrug resistance owing to the presence of multiple efflux 
transporters in several cancer models. 
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5.2. Introduction 
A major obstacle in cancer therapy is the development of multidrug resistance (MDR) in cancer 
cells. Over-expression of transporter proteins belonging to the ATP-binding cassette 
superfamily (ABC) on the cellular membrane is one of the leading causes for MDR1. ABC 
transporters utilize energy from ATP hydrolysis for drug efflux which reduces intracellular drug 
concentration to sub-therapeutic levels. At a molecular level it is generally assumed that the 
transporter binds the drug from the inner membrane while it diffuses into the cell, thus 
preventing drug entrance. Of more than 100 ABC transporters identified from prokaryotes to 
humans- P-glycoprotein (P-gp), multidrug resistance-associated protein 1 (MRP1) and breast 
cancer resistance protein (BCRP) are the most characterized phenotypes that confer drug 
resistance. P-glycoprotein (encoded by the gene ABCB1) was the first ABC-transporter to be 
identified2 followed by MRP1 (encoded by the gene ABCC1) and later BCRP (encoded by the 
gene ABCG2)3. The term BCRP is quite misleading as these transporters are not just confined to 
either cancer cells or breast cells. Apart from organs where both P-gp and BCRP are expressed 
(such as brain, intestine, liver, kidney), BCRP is present and is responsible for protective 
functions in placenta and stem cells4.  
With the discovery of BCRP in brain endothelial cells, it became established that P-gp is not the 
only efflux transporter engaged in drug efflux across the blood-brain barrier (BBB)5. The third-
generation and a broad spectrum MDR inhibitor elacridar, as well as certain tyrosine kinase 
inhibitors (gefitinib and imatinib) are some of the recently reported dual inhibitors of P-gp and 
BCRP6. However, they are not very specific towards either of these ABC transporters, which in 
turn pose risks for physiological functioning of normal cells. 
Several efforts have been undertaken to develop new potent and selective inhibitors of BCRP 
since its discovery.  Recently,  Juvale et al7,8, reported several 4-anilinoquinazolines as potent 
inhibitors. Some of the evaluated compounds showed even higher potencies than Ko143, which 
is the most potent selective BCRP inhibitor known so far. In the current study, we selected two 
newly identified quinazoline compounds (KCJ-160 and KCJ-199) having dual activity, showing 
high inhibition of BCRP and to a lesser extent of P-gp. Compounds KCJ-160 inhibited BCRP with 
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IC50 of 0.19 µM and 0.23 µM in Hoechst 33342 and pheophorbide A accumulation assays 
respectively (Table 1). KCJ-199 also showed good BCRP inhibition with IC50 of 0.42 µM and 0.61 
µM in Hoechst 33342 and pheophorbide A assays. Compound KCJ-160 was even potent than 
the known BCRP inhibitor Ko143 which produced an IC50 of 0.25 µM in Hoechst 33342 assay. 
Both KCJ-160 and KCJ-199 were also able to inhibit P-gp at lower micro-molar range, having IC50 
of 5.85 µM and 3.49 µM respectively in calcein-AM assay.   Chemical structures and inhibitory 
potencies (IC50 values) of KCJ-160 and KCJ-199 obtained in different functional assays obtained 
in earlier studies are given in Table 1. 
Compound Structure BCRP inhibition  
IC50  (µM) 
P-gp Inhibition 
IC50  (µM) 
clogP 
Hoechst 33342 
assay 
pheophorbide A 
assay 
calcein AM assay 
 
KCJ-160 
 
0.19 ± 0.01 0.23± 0.03 5.85 ± 0.79 
5.529 
KCJ-199 
 
0.42 ± 0.05 0.61 ± 0.04 3.49 ± 0.23 
5.282 
 
Table 1: Structures and cLog P values of compounds KCJ-160 and KCJ-1997,8 
Simultaneous delivery of MDR inhibitor and anti-cancer drug leads to overcoming of MDR but is 
hampered by potential pharmacokinetic interaction between the two administered entities. Of 
major limitations, is the undesirable effect on non-target normal cells where transporters play a 
major physiological role in effluxing xenobiotics and endogenous toxins. Hence, it is of 
importance to address two key issues: targeted delivery of inhibitors to tumor cells to achieve 
higher sensitization of the latter and to overcome unwanted pharmacokinetic interactions.  
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Following treatment, small molecules of anti-cancer drugs get rapidly cleared from the tissues 
such that their therapeutic concentrations cannot be maintained for longer durations. Also, 
selectivity issues in turn lead to undesired side effects of these drugs on healthy tissues. 
Combination therapies via drug delivery systems (such as nanoparticle based) offer multiple 
advantages over conventional chemotherapy9. On one hand they can protect the encapsulated 
drug/ MDR modulator from degradation in vivo and on the other hand they can address 
selectivity issues by localizing them to tumor mass. This subsequently leads to higher build up 
of intracellular chemotherapeutic molecule for a longer duration that can effectively kill cancer 
cells. Besides, MDR inhibitor loaded NP’s lead to avoidance of overlapping toxicities of the co-
delivered anti-cancer drug and inherent toxicity exhibited by inhibitors (if any). Over the past 
few years NPs have been intensively investigated as means to bypass MDR-mediated drug 
efflux10. But as cancer cells have outsmarted and evolved to express multiple efflux and survival 
proteins, so has the effort to develop multi-drug inhibitors that can inhibit multiple 
pathways/proteins.  
In this study, we developed poly-lactic-co-glycolic-acid (PLGA)-based polymeric nanoparticles 
that have been extensively evaluated as delivery platform for a variety of drugs, peptides and 
genes11. Current literature is replete with studies involving PLGA-based nanoparticles due to 
their hydrophobic nature and excellent biodegradable and biocompatible properties. As the 
MDR inhibitors in this work (KCJ-160 and KCJ-199) are lipophilic molecules, we conceived that a 
high encapsulation efficiency and sustained release could be obtained using PLGA-based 
nanocarriers.  
On the basis of high inhibitory action of the two compounds, KCJ-160 and KCJ-199 against BCRP, 
these compounds were evaluated as nanoparticle formulation. In addition to BCRP inhibition at 
very low concentrations (< 1 µM), they have demonstrated additional inhibitory activity against 
P-glycoprotein. In this work, we have shown enhanced cytotoxicity when these inhibitors were 
formulated as nanoparticles and administered with the anti-tumor drugs SN-38 and 
doxorubicin, which are BCRP and P-gp substrates respectively12,13. 
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5.3. Materials and Methods 
5.3.1. Materials 
KCJ-160 and KCJ-199 were synthesized in-house with a purity of >98% (Table 1). Poly-lactide-co-
glycolide (PLGA) RG 502 H was obtained from Boehringer Ingelheim (Ingelheim, Germany). 
Polyvinyl alcohol (PVA, Mowiol® 4-88) was a gift from Kuraray (Frankfurt, Germany) and 
Verapamil hydrochloride from Fagron (Barsbüttel, Germany). Hoechst 33342, calcein AM, 
doxorubicin hydrochloride and rhodamine-123 were purchased from Sigma-Aldrich (Steinheim, 
Germany). SN-38 and Ko143 were purchased from TCI Europe N.V. (Eschborn, Germany) and 
Tocris Bioscience (Bristol, United Kingdom) respectively. All other chemicals were of analytical 
grade.  
5.3.2. Cell lines 
Wild type MDCK and BCRP expressing MDCK cells were a kind gift from Dr. A. Schinkel (The 
Netherlands Cancer Institute, Amsterdam, The Netherlands). MDCK BCRP cells were generated 
by transfection of the canine kidney epithelial cell line MDCKII with the human wild-type cDNA 
C-terminally linked to the cDNA of the green fluorescent protein (GFP). These cells were 
cultured in Dulbecco’s modified eagle medium (DMEM) with 10 % fetal bovine serum (FBS), 50 
μg/mL streptomycin, 50 U/mL penicillin G and 2 mM L-glutamine. The human ovarian 
carcinoma cell line A2780 and the corresponding P-gp overexpressing doxorubicin resistant 
A2780Adr cell line were purchased from ECACC (Nos. 93112519 and 93112520). The cell lines 
were grown in RPMI-1640 medium supplemented with 10% FBS, 50 µL/mL streptomycin, 50 
U/mL penicillin G, and 2 mM L-glutamine. All cell lines were cultivated in a 37 °C incubator with 
5% CO2/ 95% humidified air. Subculturing was performed after confluence of 80-90%, using 
0.05 % trypsin and 0.02 % EDTA. Cell counting for different assays was performed using a CASY1 
model TT cell counter with 150 μm capillary (Schaerfe System GmbH, Reutlingen, Germany). 
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5.3.3. Preparation and characterization of nanoparticles 
NP’s were prepared by dissolving 20 mg PLGA and 1 mg each of KCJ-160 and KCJ-199 in 400 µL 
dichloromethane as internal phase. This was poured in 2 mL of 2% (w/v) PVA solution (aqueous 
phase) and ultrasonicated (50% duty cycle for 2 min). The organic phase of internal phase was 
evaporated by stirring for 3hr. Blank nanoparticles were prepared analogously without the 
addition of either inhibitor. Nanoparticles were analyzed for their size distribution, 
polydispersity index (PDI) and zeta potential using a ZetaPlus (Brookhaven Instruments 
Corporation). Each sample was analyzed in triplicate.  
5.3.4. Encapsulation efficiency and inhibitor release 
The amount of inhibitor entrapped within the NPs was detected by RP-HPLC using a column 
Eurospher II 100-5 C18H (50 x 4 mm) connected with a pre-column Vertex-Plus Eurospher II 
100-5 C18H (5 x 4 mm) obtained from Knauer, Germany. Eluent (methanol:water (70:30)) flow 
rate was maintained at 1.0 mL/min and samples were detected at 254 nm. 
In order to assess the drug release, 2 mL of each preparation was taken in triplicate and kept at 
37° C in a shaking water bath. Phosphate buffered saline (pH 7.4) was chosen as release buffer. 
0.1 % tween 80 was added to maintain sink conditions. At predefined time points 0.5 mL of 
release medium was withdrawn and replaced by 0.5 mL of fresh buffer for continuous release. 
0.5 mL of methanol was added to the withdrawn medium, vortexed and centrifuged to extract 
the released inhibitor. The supernatant was quantified for the respective MDR inhibitor by 
HPLC as mentioned before.  
5.3.5. BCRP inhibition assays 
Both Hoechst 33342 and pheophorbide A are BCRP substrates and subsequently all assays were 
performed on sensitive MDCK and BCRP expressing MDCK cell lines. Ko143 was used as positive 
control and all treatments were given at a concentration of 1µM of inhibitors and their 
equivalent NP dose. 
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5.3.5.1.  Hoechst 33342 accumulation assay 
To investigate the effect of encapsulated target compounds on BCRP, a Hoechst 33342 
accumulation assay was performed as described earlier with small modifications14. Following 
trypsization and centrifugation of MDCK and MDCK BCRP cells, the cell density was determined 
using a Casy I Model TT cell counter device. Followed by repeated centrifugation cells were 
washed three times with Krebs-Hepes buffer (KHB) and seeded into black 96-well plates 
(Greiner, Frickenhausen, Germany) at a density of approximately 20,000 cells per well in a 
volume of 80 µL. 100 µL of 1 µM inhibitors KCJ-160 and KCJ-199 and their NP equivalent were 
added and incubated for 30mins. After this pre-incubation period, 20 µL of Hoechst 33342 
solution was added to each well yielding a final Hoechst 33342 concentration of 1 µM. 
Fluorescence was measured immediately in constant intervals (60s) up to 120 min at an 
excitation wavelength of 355nm and an emission wavelength of 460nm using a BMG POLARstar 
microplate reader (BMG Labtech, Offenburg, Germany) maintained at 37 °C. For data analysis, 
obtained from the assay, the average of fluorescence values in the steady state (from 111 min 
to 120 min) was calculated for each concentration. From the obtained plateau fluorescence 
values, concentration response curves were generated by nonlinear regression using the four-
parameter logistic equation with variable Hill slope (GraphPad Prism v. 5.0, San Diego, CA, USA). 
5.3.5.2. Pheophorbide A Assay 
To re-evaluate the effect of encapsulated target compounds on BCRP using another BCRP 
substrate, a pheophorbide A assay was performed14,15,16. For performing the pheophorbide A 
assay, cells were prepared in the same manner as described for the Hoechst 33342 assay. The 
assay was done in a clear, U-shaped 96-well plate, with a final concentration of pheophorbide A 
of 0.5 µM. Following an incubation period of 2hr, cells were again re-suspended using a 
multichannel pipette. Fluorescence was measured using a FACSCalibur flow-cytometer. 
Concentration-response curves were generated by nonlinear regression using the four-
parameter logistic equation using GraphPad Prism (v. 5.0, San Diego, CA, USA).  
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5.3.6. P-gp inhibition assays  
Both calcein AM and rhodamine-123 are P-gp substrates and subsequently all assays were 
performed on sensitive A2780 and P-gp expressing A2780Adr cell lines to evaluate P-gp 
inhibitory activity of compounds and their NP’s. Verapamil hydrochloride was used as positive 
control and all treatments were at a concentration of 5 µM of inhibitors and their equivalent NP 
dose. 
5.3.6.1. Calcein AM accumulation assay 
For determining the effect of encapsulated target compounds on P-gp a calcein AM 
accumulation assay was performed as described earlier with small modifications14,17. Cells were 
prepared in the same manner as described for the Hoechst 33342 assay. After a 30 min pre-
incubation period, 20 µL of a 2.5 µM calcein AM solution was added to each well. The 
fluorescence was measured immediately in constant time intervals (60s) up to 360 min at an 
excitation wavelength of 485 nm and an emission wavelength of 520 nm with a BMG POLARstar 
microplate reader maintained at 37°C. 
5.3.6.2. Rhodamine-123 uptake assay 
To re-evaluate the effect the inhibitors on P-gp, a rhodamine-123 accumulation assay was 
performed as it is a known P-gp substrate. 10,000 cells each of A2780Adr and A2780 were 
seeded in 96 well plates and incubated overnight for adherence. On the next day, inhibitor and 
equivalent NP treatment were given at 5µM together with rhodamine-123 solution yielding a 
final concentration of 0.3 µM. The total volume per well was kept at 100µL. Following 
incubation for 6hr, media was removed, and wells washed once with PBS. 100µL Triton-X 100 
(1% v/v) was added to each well and incubated for 30min to lyse cells and extract rhodamine-
123. The fluorescence was measured (ex = 505 nm, em = 540 nm) with a fluorescence 
spectrophotometer (Victor3, Perkin Elmer) and normalized for cellular protein levels as 
determined by bicinchoninic acid (BCA) assay. 
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5.3.7. Confocal Laser Scanning Microscopy  
Cells were grown over coverslips in 24-well plate and incubated with doxorubicin (0.5µg/mL), 
both inhibitors and their respective formulations for 6hr. Free doxoorubicin was removed by 
several washing steps followed by incubation with wheat germ agglutinin-FITC at 4°C for 30min. 
Fixation was performed with paraformaldehyde (4%) followed by nuclear staining with DAPI 
(300nM; 5min). Slides were prepared with glycerol/PBS and imaged with a Biorad Laser 
Scanning Confocal Imaging System 
5.3.8. Cytotoxicity with doxorubicin 
To check the effectiveness of encapsulated inhibitors to reverse the drug resistance in BCRP 
(MDCK BCRP) and P-gp (A2780Adr) over-expressing cells to SN-38 and doxorubicin respectively, 
MTT cytotoxicity assays were performed. The sensitive counterparts of these cells were used as 
controls. The assay was performed as described earlier with minor modifications14,18. In brief, 
cells were seeded overnight into 96-well tissue culture plates (Sarstedt, Newton, USA) at a 
density of 3000 cells  (for MDCK cells)  or 5000 cells (for A2780 cells) per well in a volume of 80 
µL for adherence. Cells were treated with cytotoxic compounds (SN-38 or doxorubicin) at 
different concentrations in a volume of 10 µL. Target compounds and encapsulated compounds 
were added to each well at a final concentration of 1 µM (BCRP) or 5 µM (P-gp) to achieve the 
final volume of 100 µL. Control experiments were performed with medium containing 10% (v/v) 
DMSO.  After an incubation period of 72hr, the MTT reagent was added (20 µL of a 5 mg/mL 
solution) to each well. Plates were further incubated for 1hr and after that the supernatant 
were removed from wells. Formazan crystals formed were solubilized by adding 100 µL DMSO 
per well. Viability of cells was measured by taking absorbance at 544 nm and background 
corrected at 710 nm (BMG POLARstar microplate reader). 
5.3.9. Statistical Analysis 
All the experiments were performed in triplicates and reported as mean ± S.D. Statistical 
comparisons were made with one-way ANOVA followed by Dunnett’s post test using GraphPad 
  5. Chapter 3 
 
90 
 
Prism software version 5.0. In all cases, p< 0.05 was considered to be significant at 95% 
confidence level. 
5.4. Results 
5.4.1. KCJ-160 & KCJ-199 loaded polymeric nanoparticles  
The physicochemical properties of the three formulations are shown in Table 2. Blank and 
inhibitor (KCJ-160 and KCJ-199) loaded nanoparticles did not differ much in size ranging from 
315 to 358 nm. Encapsulation efficiency as determined by HPLC was influenced by the slight 
difference in lipophilicity of the compounds, wherein the more lipophilic inhibitor KCJ-160 
showed comparatively higher encapsulation.   
 Size (nm) PDI Zeta potential Encapsulation 
efficiency (%) 
Blank NP 358 ± 8 0.04 ± 0.02 -12.8 ± 1.2 - 
KCJ-160 NP 315 ± 14 0.05 ± 0.03 -11.4 ± 0.2 77.1 ± 0.5 
KCJ-199 NP 327 ± 11 0.04 ± 0.01 -10.6 ± 0.3 69.0 ± 1.6 
 
Table 2. Nanoparticle size, PDI, zeta potential and encapsulation efficiency of inhibitors (n=3, mean ± 
S.D.) 
5.4.2. Encapsulation efficiency and release  
Cumulative release of dual MDR inhibitors showed a sustained release profile with the more 
lipophilic inhibitor KCJ-160 showing comparatively slower release rate (Figure 1). The release 
was observed for over a week (one week data not shown) and samples analyzed by HPLC. 
About 46% and 54% of KCJ-160 and KCJ-199, respectively, were released in first 6hr and most 
assays were performed with incubation times ranging 2-6hr. 
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Figure 1. Cumulative release profile of KCJ-160 and KCJ-199 from NP in PBS (pH 7.4) at different time 
points (n=3, mean ± S.D.) 
5.4.3. BCRP inhibition 
On the basis of highly potent inhibitory action of the two compounds, KCJ-160 and KCJ-199 
against BCRP, these compounds were evaluated as nanoparticle formulation. Two well 
characterized BCRP substrates, Hoechst 33342 and pheophorbide A were used as probes to 
assess BCRP inhibition in BCRP over-expressing MDCK cell lines. In both the assays, the potent 
inhibitor Ko143 was used as a positive control. Ko143 is a non-toxic analogue of fumitremorgin 
C (FTC) and the only known specific and potent modulator of BCRP with high affinity to the 
latter16.  
5.4.3.1. Hoechst 33342 assay 
Hoechst 33342 influx across cell membrane increases when BCRP is inhibited by a modulator. 
This leads to an increase in fluorescence of cellular Hoechst 33342 implying efficient BCRP 
inhibition. We observed high accumulation of Hoechst 33342 in BCRP overexpressing cells 
within 2.5hr of inhibitor and equivalent NP dose treatment (Figure 2A). Both inhibitors were 
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potent enough at a concentration as low as 1µM resulting in complete reversal of drug 
resistance.  
5.4.3.2. Pheophorbide A assay 
Pheophorbide A, a chlorophyll-breakdown product is another known BCRP substrate.  As it 
diffuses readily across the cell membrane, the accumulation per cell can be measured using 
flow cytometry. In BCRP overexpressing cells, pheophorbide A accumulation was enhanced 
following treatment with inhibitors (both solution and NP) (Figure 2B). These results were 
similar to those obtained in Hoechst 33342 accumulation assay. KCJ-160 which showed better 
accumulation (as both free solution and NP) as compared to KCJ-199 has been shown 
previously8 to be more potent in Pheophorbide A assay (Table 1). Consequently, KCJ-199 NP did 
not show much potency either as the free inhibitor itself.  
2A. 
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2B 
 
Figure 2A. Hoechst 33342 accumulation assay in BCRP expressing MDCK and sensitive cells.  2B. 
Pheophorbide A accumulation assay in BCRP expressing MDCK and sensitive cells.  (Mean ± S.D.; n = 6; 
*p < 0.001, One-way ANOVA followed by Dunnett’s multiple comparison test). The dotted line 
represents basal Hoechst 33342 or pheophorbide A accumulation in resistant cells without any 
treatment. 
5.4.4. P-gp inhibition assay 
5.4.4.1. Calcein AM accumulation assay 
The ability of inhibitor and their corresponding NP’s to modulate P-gp function was evaluated 
using the calcein AM assay in P-gp over-expressing A2780Adr cells (Figure 3A). Following 
diffusion, calcein AM gets hydrolyzed to calcein anion by esterases present in cells. Unlike 
calcein AM, calcein is strongly fluorescent and being hydrophilic, cannot leave cells by diffusion. 
In P-gp overexpressing resistant cells, the fluorescence increase caused by intracellular calcein 
was measured as a function of P-gp inhibition.  KCJ-160 has been previously shown8 to possess 
P-gp inhibitory activity to a lesser extent as compared to KCJ-199. But when encapsulated in 
particles, KCJ-160 shows an increased calcein accumulation. This could be possible due to 
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higher cellular uptake of nanoparticles as well as prolonged sensitization of cells to the inhibitor 
(6hr incubation in this assay). In contrast, solution and NP formulation of KCJ-199 showed high 
inhibitory activity on P-gp, leading to accumulation of calcein equivalent to that in sensitive 
cells. 
5.4.4.1. Rhodamine-123 uptake assay 
Rhodamine-123, a fluorescent dye which is readily effluxed by P-gp expressing cells is routinely 
used to study the MDR phenomenon. Rhodamine-123 uptake increased in all treatment groups 
including blank NP (Figure 3B).  Accumulation was slightly enhanced with both KCJ-160 and KCJ-
199 (solution and NP) as compared to the first generation P-gp inhibitor verapamil used as 
positive control.  However, all treatment groups showed high P-gp inhibition leading to 
increased rhodamine-123 accumulation at par with the uptake in A2780 cells. Following 6hr 
incubation, both NP preparations showed better uptake. 
3A. 
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Figure 3A. Calcein accumulation assay in P-gp expressing A2780Adr and sensitive A2780 cells. 3B. 
Rhodamine-123 accumulation normalized against protein levels in P-gp expressing A2780Adr and 
sensitive A2780 cells. (Mean ± S.D.; n = 6; *p < 0.001 compared with A2780Adr, one-way ANOVA 
followed by Dunnett’s multiple comparison test). The dotted line represents basal calcein and 
rhodamine-123 accumulation in resistant cells without any treatment. 
 
5.4.5. Confocal microcsopy 
Chemosensitization of resistant and sensitive cells were performed to qualitatively analyze 
doxorubicin uptake (Figure 4). After 6hr treatment, drug resistant cells A2780Adr showed little 
doxorubicin uptake (Figure 4a.) in contrast with sensitive cell lines- A2780 (Figure 4b.). MDR 
reversal was observed in A2780Adr cells treated with KCJ-199 solution, KCJ-160NP and KCJ-
199NP. However, the uptake was not increased significantly in KCJ-160 solution treatment 
group. 
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Figure 4. Confocal images of A2780Adr and A2780 cell lines. The cells were incubated for 6hr with 
different inhibitors and their formulations and doxorubicin (red channel). b. A2780- doxorubicin treated; 
while rest are A2780Adr images treated with free doxorubicin and a. A2780Adr- doxorubicin alone; c. 
KCJ-160 solution; d. KCJ-160 NP; e. KCJ-199 solution; f. KCJ-199 NP The cell membrane was stained with 
wheat germ agglutinin-FITC (green) and the nucleus with DAPI (blue). Scale bar represents 5µm.  
 
5.4.6. Cytotoxicity with doxorubicin 
To determine the MDR reversal ability of inhibitors and their nanoparticle counterparts, the 
MTT assay was performed using the BCRP substrate SN-38 and the P-gp substrate doxorubicin. 
Sensitive and resistant cells were incubated with cytotoxic compounds (SN-38 or doxorubicin) 
and a fixed concentration of the inhibitors or their NPs for 72hr. Exposure to dual inhibitors and 
their NP formulations resulted in sensitization of resistant cells. In both BCRP and P-gp 
expressing cells, NP’s gave encouraging results with lower growth inhibition-GI50 values 
achieving complete reversal.  This was largely due to sustained release of inhibitors from within 
nanoparticle over the period of treatment. 
  5. Chapter 3 
 
97 
 
Marked reduction in GI50-values of SN-38 in BCRP over-expressing MDCK BCRP cells were 
observed following treatment with KCJ-160 (solution and NP) and KCJ-199 NP (Figure 5). KCJ-
199 solution exhibited slightly less efficacy as compared to KCJ-160, which was also observed in 
Hoechst 33342 (Figure 2A) and pheophorbide A assays (Figure 2B).  
NP-based inhibition of P-gp over-expressing, A2780Adr cells gave very promising results (Figure 
6). KCJ-160 NP and KCJ-199 NP were able to overcome MDR efflux with a reversal efficacy of 
more than 3-fold than any of the inhibitors (Verapamil, KCJ-160 & KCJ-199) administered as free 
solutions. Reversal efficacies of both KCJ-160 and KCJ-199 formulations were higher than that 
of their respective solutions (Table 4). 
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Figure 5. GI50 values of SN-38 in BCRP over-expressing MDCK cells and wild type (MDCK) as calculated by 
the MTT assay. (Mean ± S.D.; n = 3; *p < 0.05 compared to MDCK BCRP (untreated), one-way ANOVA 
followed by Dunnett’s post test.) 
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Figure 6. GI50 values of doxorubicin in P-gp over-expressing A2780Adr cells and wild type (A2780) as 
calculated by the MTT assay. (Mean ± S.D.; n = 3; *p < 0.05 compared to MDCK BCRP (untreated), one-
way ANOVA followed by Dunnett’s post test.) 
Reversal efficacy and resistance factor were calculated from GI50 values with the following 
formulas: 
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Figure 7A. Resistance factor is the quotient of GI50 value of treatment group in BCRP over-expressing cell 
line to that of the untreated sensitive cell line (MDCK). Res (U) refers to untreated resistant cell line 
MDCK-BCRP. (*p< 0.05 by one-way ANOVA followed by Bonferroni post t-test.)       
 
Figure 7B. Resistance factor is the quotient of GI50 value of treatment group in P-gp over-expressing cell 
line to that of the untreated sensitive cell line (A2780). Res (U) refers to untreated resistant cell line 
A2780Adr. (*p< 0.05 by one-way ANOVA followed by Bonferroni post t-test.) 
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5.5. Discussion 
Two newly synthesized 4-anilinoquinazoline compounds- KCJ-160 and KCJ-199 were chosen for 
present work due to their ability to inhibit both MDR transporters BCRP and P-gp. PLGA-based 
nanoparticles of both inhibitors were developed by solvent evaporation technique. Particles in 
the size range 300 to 365 nm showed good polydispersity index and negative surface charge 
due to PLGA (Table 2). Both compounds possessing high lipophilicity had an effect on 
encapsulation efficiency and rate of release from nanoparticles. KCJ-160, being more lipophilic 
than KCJ-199 showed comparatively higher encapsulation efficiency (77.1 ± 0.5%) in 
nanoparticles and a slower rate of release (Figure 1) which could be explained due to increased 
hydrophobic interactions with the polymer PLGA. We used PLGA-based nanoparticles as 
hydrophobic compounds tend to release at a sustained rate via diffusion of drug from the 
polymer matrix, which may prolong inhibitory action and thereby higher sensitization of 
resistant cells towards cytostatic drugs can be achieved. 
The efficiency of both inhibitors are proven8 with a high potency against BCRP but to a lesser 
extent against P-gp. Two pairs of cell lines that over-express each transporter (BCRP and P-gp) 
were used in this study. The most characterized and quantifiable substrates were selected for 
each transporter. As positive controls, inhibition of each transporter was evaluated with a 
known inhibitor (Ko143 and verapamil). 
The inhibition activity of both the inhibitors and their NP counterparts were indicated by their 
ability to inhibit efflux of fluorescent substrates- Hoechst 33342 and Pheophorbide A in BCRP 
overexpressing MDCK-BCRP cells. Increased accumulation of Hoechst 33342 (Figure 2A) and 
Pheophorbide A (Figure 2B) were observed with both inhibitors and at equivalent concentration 
of NPs. Accumulation of fluorescent substrates in the sensitive cell line- MDCK, did not change 
in the presence or absence of either inhibitors or nanoparticles (data not shown). Complete 
reversal of drug resistance could be demonstrated (equivalent to parental cell line) well within 
2.5hr of assay. KCJ-199 is less potent than KCJ-160 in inhibiting BCRP against Pheophorbide A 
accumulation (Table 1) which is consistent with results obtained in the work of Juvale et al8. 
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This could be extrapolated to explain lower Pheophorbide A accumulation with KCJ-199 NP 
treatment. 
Accumulation of the fluorescent substrates- calcein and rhodamine-123 in P-gp over-expressing 
A2780Adr were evaluated as markers for inhibitory potency of both compounds and their NPs. 
As these inhibitors have lower P-gp inhibition ability, a prolonged incubation (6hr) at higher 
concentrations (5μM) of inhibitor and respective NPs were carried out to achieve maximum 
sensitization.  In line with observations of Juvale et al8, KCJ-160 showed lower inhibition of P-gp 
as compared to KCJ-199. However, it is interesting to note that although KCJ-160 does not 
possess high inhibitory activity against P-gp, when delivered via nanoparticle, it showed 
significantly high inhibition in both assays. This might be due to the intracellular delivery of KCJ-
160 NPs within cells from where the inhibitor can exert a higher action against P-gp transporter 
molecule. KCJ-160 NP, KCJ-199 solution and NP demonstrated high inhibition potency against P-
gp in terms of accumulation of calcein and rhodamine-123.  
To reaffirm the results obtained with fluorescent substrates, the inhibitory potential of 
compounds and NPs was also evaluated by checking their effect on resistance of cells towards 
cytotoxic substrates of each transporter. For this purpose, anti-cancer drugs SN-38 (BCRP 
substrate) and doxorubicin (P-gp substrate) were used in MTT assay. As an extrapolation of 
Hoechst and pheophorbide A assay, complete reversal of resistance in BCRP over-expressing 
cells (MDCK-BCRP) was achieved, marked by GI50 value of SN-38 nearing that of parental cell 
line (MDCK). In P-gp over-expressing cell lines, inhibitor loaded nanoparticles gave much higher 
sensitization than the inhibitors alone. Fluorescent substrate assays with both calcein and 
rhodamine-123 did not show clear result in terms of complete sensitization and statistical 
significance amongst the groups. Only KCJ-160 showed similar results and demarcated lower 
inhibition potency against P-gp transporters as compared to KCJ-199, even with doxorubicin. 
Confocal images of drug resistant and sensitive cell lines demonstrated similar results as the 
accumulation assays for P-gp inhibition with very high uptake  of doxorubicin in both NP treated 
groups (Figure 4d,f.). 
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Following 72h incubation with doxorubicin and both the inhibitors and their respective NPs, 
very encouraging results were obtained. KCJ-160 and KCJ-199 NPs decreased the resistance of 
P-gp cell lines to doxorubicin by over 5-fold (p< 0.001) and over 2-fold (p< 0.01) as compared to 
their free solution respectively (Figure 7A). Both inhibitors, which possess lesser activity against 
P-gp transporter demonstrated almost complete reversal of drug resistance when delivered as 
nanoparticles. This might be due to sustained rate of release of inhibitor from the PLGA matrix 
over a period of time leading to sensitization of resistant cells to near completion and 
eventually killing them. However, in BCRP over-expressing cells, sensitization achieved with 
solution and NP formulations were at par showing equal therapeutic efficiency (Figure 7B). 
Although several efforts have been taken to identify selective inhibitors of BCRP as well as P-gp, 
broad-spectrum MDR modulators have the advantage of countering multiple resistance 
mechanisms that could be present in the therapy resistant tumour/malignant cells.  It has been 
observed that clinically important substrates of ABCG2 may possess overlapping substrate 
specificity also for P-gp. Few of these substrates include anticancer compounds such as 
topotecan, gefitinib, erlotinib, flavopiridol and mitoxantrone. In such cases broad spectrum ABC 
transporter inhibitors could be advantageous. 
This study highlights the importance of nanocarriers in delivery of MDR inhibitors. A delivery 
platform not only helps improve solubility issues of lipophilic compounds, when injected 
intravenously nanoparticles can increase inhibitor/ drug accumulation within tumor tissue due 
to the enhanced permeability and retention effect19. In a recent study, P-gp modulator-
valspodar loaded methoxy-poly(ethylene oxide)-block-poly(e-caprolactone) (PEO-b-PCL) 
micelles were developed20. Intravenous administration of micelles significantly lowered the 
clearance and volume of distribution of valspodar and an increase in plasma area-under the 
curve (AUC) was observed compared to when valspodar was given in Cremophor® EL 
formulation. Administration of valspodar loaded micelles reduced the pharmacokinetic 
interactions with doxorubicin in Sprague-Dawley rats in in vivo studies21.  
Hence, using drug delivery system can reduce the effective doses of MDR modulator required 
to attenuate transporter function in drug resistant cells. A sustained release profile and an 
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enhanced bioavailability of these inhibitors at the pharmacological site of action can lead to 
higher and prolonged sensitization of drug resistant tumors. From this work we can conclude 
that NP formulations of dual inhibitors may as well lead to better efficacy in overcoming MDR in 
tissues such as the blood-brain barrier which show over-expression of multiple efflux 
transporters5. As the cell lines used in this study were of canine and human origin, it was not 
feasible to conduct in vivo experiments on animal models. However, it would be highly 
desirable to compare pharmacokinetic and MDR modulatory activity of inhibitor and their 
respective NP formulations in animal model for further clinical translatability. 
5.6. Conclusion 
Two newly identified potent BCRP/ P-gp inhibitors- KCJ-160 and KCJ-199, were formulated into 
PLGA-based nanoparticles. The compounds have shown higher potency against BCRP and to a 
lesser extent in P-gp. Nanoparticle formulations (carrying equivalent inhibitor dose) exhibited 
complete reversal of drug resistance in two pairs of cell lines that over-expressed each 
transporter (BCRP and P-gp). Both inhibitors having high potency against BCRP, showed 
complete sensitization of BCRP expressing cell lines when formulated as nanoparticle. However, 
the most promising results were against P-gp where nanoparticles performed better than the 
inhibitor solution of both compounds. The results clearly establish that the sensitization of cells 
can be achieved with sustained delivery of inhibitors as obtained from nanoparticle 
formulations of respective inhibitors. To the best of our knowledge this is the first report on 
BCRP inhibitor loaded nanomedicinal intervention. This study is also the first to evaluate dual-
inhibitors loaded nanocarriers with inhibitory potential against multiple transporters (BCRP and 
P-gp). 
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6.  Summary and Conclusion 
Failure of chemotherapy due to development of multidrug resistance (MDR) in cancer has lead 
to diminishing treatment options. ATP-binding cassette (ABC) superfamily of trans-membrane 
transporters is responsible for drug efflux of which P-glycoprotein (P-gp) is the most 
characterized. Following decades of research, there is little clinical benefit in terms of MDR 
modulation spanning three generations of MDR inhibitors. This has been attributed to 
pharmacological disadvantages associated with most inhibitors such as their poor specificity 
and low availability at the tumor site.  
Nanocarriers offer promise as drug delivery vehicles of anti cancer drug/ MDR inhibitor and in 
overcoming drug resistance in cancer, as exemplified by many successful outcomes in last few 
years. Recently, certain excipients/ surfactants which are routinely applied in the 
pharmaceutical industry to improve solubility and bioavailability of the drug have shown ability 
to inhibit the MDR transporters in drug resistant tumors.  
In the first part of this work, various excipient-based nanoparticles were developed. As the 
nanoparticle surface first to interact with cell membrane, presence of ‘surface active’ excipient 
molecule was conceptualized to modulate P-gp transporter present on the membrane as soon 
as the two come in contact. We observed that, Cremophor® EL and CTAB-based nanoparticles 
increased the sensitivity of highly resistant glioma cell lines to doxorubicin by up to 4.7-fold in 
comparison to the treatment with anti-cancer drug alone. SDS-based nanocarriers improved 
cytotoxicity marginally, Solutol® HS15 and Tween® 80 did not exhibit considerable 
chemosensitization as formulations. 
Thus, with ‘surface active’ NPs, sensitization achieved was ascribable entirely to the particles 
devoid of any MDR inhibitors. Although, inherently active nanocarriers demonstrated potential; 
encapsulating MDR inhibitors can lead to synergistic and enhanced anti-MDR effects to achieve 
complete inhibition of ABC transporters. 
In order to evaluate the effect of MDR-inhibitors, we chose inhibitors of first and third 
generation- Verapamil hydrochloride and Elacridar respectively; and to see the effect of surface 
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charge, representative of each of non-ionic, cationic and anionic excipients were used. Amongst 
the different categories of surfactants used, MDR inhibitor loaded CTAB nanoparticles gave very 
promising results with respect to reversal in drug resistant cell lines as compared to anionic and 
non-ionic inhibitor-loaded nanoparticles. To chalk out possible mechanism of NP uptake, 
various pharmacological inhibitors were used and it was observed that a caveolae-mediated 
endocytosis might be in effect. Nanoparticle uptake appeared to be influenced by size and not 
by charge, as the difference in mechanism of uptake was not significantly different amongst 
cationic, anionic and non-ionic particles.  
The higher responses with CTAB-nanoparticles can be explained on the basis of adhesion of 
cationic CTAB nanoparticles to the negatively charged cell membrane which have been 
investigated previously and were also confirmed in this work as observed by confocal laser 
scanning microscopy. 
Besides P-gp, breast cancer resistance protein (BCRP) are another set of efflux transporters of 
the ABC superfamily which were initially discovered in drug resistant breast cancer cell lines but 
later found to be expressed in other key tissues including blood-brain barrier and 
gastrointestinal tract.  Research is underway to develop ABC inhibitors which can target 
multiple efflux transporters. However, as affinity for multiple ABC transporters seems to 
broaden the functionality of such dual inhibitors, the compass of potential side effects also 
raises. Hence, it is imperative to deliver them in nanocarriers so as to bypass the 
transmembrane without their recognition by drug transporters.  
Recently developed quinazoline compounds KCJ-160 and KCJ-199 demonstrate high inhibitory 
potency against BCRP transporters and to a lesser extent P-glycoprotein. The compounds were 
formulated as nanoparticles, characterized and assessed in relevant BCRP and P-gp over-
expressing drug-resistant & drug-sensitive cell lines. Nanoparticles offered particularly 
interesting results due to their ability to release encapsulated inhibitors over a prolonged 
period resulting in higher sensitization of drug resistant cells, in contrast to the soluble 
inhibitors which offered shorter duration of activity. Complete reversal of drug resistance can 
therefore be achieved using inhibitor-loaded nanoparticles.  
